A tyrosine kinase inhibitor for use in the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation

WO2026215634A3PCT designated stage Publication Date: 2026-11-19THE UNIV OF READING
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2026/050631
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-03-16
Filing Date
2026-04-10
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current antivenoms are largely ineffective against severe local envenoming from snakebites, leading to significant muscle damage, fibrosis, and permanent disabilities, and matrix metalloprotease inhibitors like marimastat worsen muscle fibrosis, while existing treatments are expensive and challenging to administer.

Method used

A combination therapy using a tyrosine kinase inhibitor (e.g. nilotinib) with a phospholipase A2 inhibitor (e.g. varespladib) and/or a matrix metalloprotease inhibitor (e.g. marimastat) to prevent, treat, inhibit, or ameliorate the effects of envenomation by snake venom, promoting tissue regeneration and reducing fibrosis.

Benefits of technology

The combination therapy significantly reduces venom-induced fibrosis, promotes muscle regeneration, and increases survival rates, offering a more stable and easier-to-administer alternative to antivenom, particularly effective against venoms where antivenoms are ineffective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GB2026050631_19112026_PF_FP_ABST
    Figure GB2026050631_19112026_PF_FP_ABST
Patent Text Reader

Abstract

A tyrosine kinase inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMBINATION THERAPY FOR ENVENOMATION

[0002] Field of the Invention

[0003] The present invention relates to the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation, especially by snake venom. The present invention employs a phospholipase A2 (PLA2) inhibitor, a matrix metalloprotease inhibitor, and / or a tyrosine kinase inhibitor.

[0004] Background of the Invention

[0005] Envenomation, especially from snakebites, remains the deadliest of the neglected tropical diseases, with its burden overwhelmingly on rural communities in low- and middle-income countries. Snakebites result in as many as 140,000 deaths every year across the world. Morbidity (i.e. permanent disabilities) from snakebite envenomation affects approximately 400,000 people annually worldwide. Envenomation, especially from snakebites, can cause significant muscle damage, fibrosis and haemorrhage. Tissue damage at the bite site often leaves victims with catastrophic life-long injuries and is largely untreatable by current antivenoms.

[0006] While phospholipase A2S (PLA2S) and some three-finger toxins (3FTXs) present in venoms cause direct myotoxicity by affecting the membrane, metalloproteases present in venoms degrade various components (primarily collagen) of the extracellular matrix (ECM) around the skeletal muscle and blood capillaries. As the ECM acts as a robust scaffold to promote innate muscle regeneration, its extensive damage detrimentally affects regeneration and often results in unwarranted fibrosis and muscle loss, leading to permanent disabilities. The degradation of the ECM around blood vessels / capillaries leads to excessive bleeding, thrombotic complications, venom-induced consumption coagulopathy and other clotting disturbances. PLA2S are present in elapid and viper venoms, metalloproteases are predominantly present in viper venoms, and 3FTXs are predominantly present in elapid snake venoms. Most medically important viper venoms cause extensive muscle damage, which conventionally requires prompt clinical attention to save limbs.

[0007] Current antivenoms are largely ineffective against severe local envenoming, which involves painful progressive swelling, blistering and / or tissue necrosis / muscle damage around the bite site. This can lead to loss of limb function, amputation and lifelong disability. Developing safe, affordable, and easy-to-administer treatments will be critical in achieving the World Health Organisation's (WHO) goal to halve snakebite-related deaths and disabilities by 2030.Surgical treatments, such as debridement, fasciotomy and amputations, are used to manage the effects of local envenomation. These are expensive, challenging to perform, and often result in the removal of significant amounts of tissue and / or limbs, leading to permanent disabilities.

[0008] Publications have described that the use of 2,3-dimercapto-l -propanesulfonic acid (DMPS), marimastat, and varespladib, alone or in combinations, inhibit the cytotoxicity of a range of snake venoms; and that dual therapeutic combination of DMPS or marimastat with varespladib significantly inhibit the dermonecrotic activity of snake venoms (e.g. US2023054792A1, Albulescu, LO., et al., Nat Commun 11, 6094 (2020). doi:10.1038 / s41467-020-19981-6; Hall et al., Nat Commun. 2023;14:7812, doi: 10.1038 / s41467-023-43510-w).

[0009] Due to the functional similarities between matrix metalloproteases in humans and venom metalloproteases from snakes, it would be expected that matrix metalloprotease inhibitors would prevent venom-induced damage to the ECM and promote muscle regeneration without fibrosis. Surprisingly, trials performed by the present inventors have shown that matrix metalloprotease inhibitors such as marimastat worsen muscle fibrosis in a subject suffering from snakebite envenomation.

[0010] Summary of the Invention

[0011] According to a first aspect, the claimed invention provides a tyrosine kinase inhibitor (e.g. nilotinib) for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject.

[0012] It has been found that tyrosine kinase inhibitors such as nilotinib provide significant and surprising effects in relation to the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject.

[0013] Specifically, tyrosine kinase inhibitors such as nilotinib have surprisingly been found to be able to provide a dramatic reduction in venom-induced fibrosis. In some instances, tyrosine kinase inhibitors such as nilotinib have been found to completely prevent fibrosis following venom-induced damage.

[0014] Muscle tissues treated with compositions comprising nilotinib following envenomation have exhibited substantially reduced amounts of damage and up to full regeneration of the tissue.

[0015] Increased levels of the structural molecules laminin and dystrophin have been detected in envenomated muscle tissue treated with compositions including nilotinib. The presence of higherlevels of these structural molecules indicates the increased health of the muscle tissues following treatment with compositions including nilotinib.

[0016] Furthermore, decreased levels of markers associated with cellular and tissue repair, immunoglobulin G (IgG), cluster of differentiation 31 (CD31) and platelet-derived growth factor receptor a (PDGFRa) were detected in envenomated muscle tissue treated with compositions including nilotinib. The lower levels of these markers further indicate the reduced damage in tissues following envenomation following treatment with compositions including nilotinib.

[0017] Some previous studies have examined the effects of nilotinib in the treatment of the effects of a single component of snake venom, such as a 3FTX. However, snake venom is a combination of several different toxins. As such, the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation present a significantly more difficult challenge compared to the treatment of the effects of a single component of snake venom, and the results presented herein are particularly surprising.

[0018] Particularly beneficial results have been obtained where the tyrosine kinase inhibitor is administered with a PLA2 inhibitor (e.g. varespladib) and / or administered with a matrix metalloprotease inhibitor (e.g. marimastat). As such, the method of the compound for use of the first aspect may further comprise administering a phospholipase A2 (PLA2) inhibitor (e.g. varespladib) and / or administering a matrix metalloprotease inhibitor (e.g. marimastat).

[0019] In survival studies examining the effects of treatment with a combination of a tyrosine kinase inhibitor (nilotinib), a PLA2 inhibitor (varespladib), and a matrix metalloprotease inhibitor (marimastat) following envenomation by one of a broad range of venoms, the combination was found to provide higher rates of survival than control (no treatment following envenomation -only the vehicle control was administered). Against all but one venom tested, the control achieved 100% mortality in less than 48 hours. However, treatment of envenomation with the combination of compounds of the invention was found to provide significant improvements to the chance of survival of the subject compared to no treatment. Further benefits may also be attained in relation to the reduction of disabling injuries of subjects when envenomation is treated with the combination of compounds of the invention. Indeed, the muscle damage induced by the venoms of Echis ocellatus, Bothrops atrox, Crotalus atrox and Bitis arietans was significantly mitigated by the combination of drugs.

[0020] In other survival studies, the combination of compounds of the invention has been found to achieve higher survival rates than high-dose antivenom.In some cases, when the combination of drugs was administered in multiple doses, it significantly extended the survival of mice compared to a single dose only.

[0021] In some cases the combination of compounds of the invention is less effective in the long term than high doses of antivenom used; however, as the combination of compounds of the invention is significantly more stable and easier to transport than antivenom and can be administered in humans in multiple doses over several days, the combination can still provide significant benefits even when this is the case. For example, rapid treatment of a subject that has been bitten by a snake with the combination of compounds of the invention may increase the chance that the subject remains alive, or in a better condition, before they can be administered with antivenom. This may help to improve the long-term prognosis of the subject.

[0022] For some snake venoms, such as Hypnale hypnale, against which the currently used antivenoms are not effective, the combination of compounds of the invention can effectively and significantly enhance survival rates following such envenomation.

[0023] In one haemorrhagic assay, control mice (no treatment following envenomation) demonstrated significantly more haemorrhage than mice treated with the combination of compounds of the invention. This shows that the combination of compounds of the invention prevents venom-induced excessive bleeding. This beneficial effect was consistently observed across multiple snake venoms used in this assay.

[0024] In another haemorrhagic assay, it was found that other tyrosine kinase inhibitors (combined with varespladib and marimastat) can still reduce bleeding. Bcr-Abl tyrosine-kinase inhibitors may be more effective than other types of tyrosine kinase inhibitors, and second-generation Bcr-Abl tyrosine-kinase inhibitors may be more effective than other generations of Bcr-Abl tyrosinekinase inhibitors. Particular benefits were observed when the combination included nilotinib as the tyrosine kinase inhibitor, compared to other tyrosine kinase inhibitors.

[0025] According to a second aspect, the claimed invention provides a kit comprising a tyrosine kinase inhibitor (e.g. nilotinib), and either or both of a phospholipase A2 (PLA2) inhibitor (e.g. varespladib) and a matrix metalloprotease inhibitor (e.g. marimastat). The PLA2 inhibitor, the tyrosine kinase inhibitor and the matrix metalloprotease inhibitor may each be referred to as a component of the invention.The claimed invention has been found to provide significant and surprising results in relation to the prevention, treatment, inhibition, delay and / or amelioration of the effects of an envenomation.

[0026] As shown by the Examples, in an in vivo study, a combination of PLA2 inhibitor (varespladib), tyrosine kinase inhibitor (nilotinib) and matrix metalloprotease inhibitor (marimastat) completely prevented fibrosis and promoted tissue regeneration following venom-induced damage, and the muscle looked very similar to the undamaged control muscles.

[0027] This is particularly surprising because, as shown by the Examples, long-term use of marimastat, either alone or in combination with varespladib, can detrimentally affect muscle regeneration, leading to smaller fibres and fibrosis. However, in the claimed invention, the administration of marimastat with varespladib and nilotinib provides better results than the combination of varespladib and nilotinib alone.

[0028] As shown in the Examples, in vivo studies have shown that the claimed components prevent venom-induced muscle damage.

[0029] As shown in the Examples, in vivo studies have shown that the claimed components prevent venom-induced muscle fibrosis.

[0030] Furthermore, as shown in the Examples, in vivo studies have shown that the claimed components can promote complete muscle regeneration following venom-induced damage.

[0031] It has been found that the components of the claimed kit can surprisingly provide synergistic effects compared to the components themselves.

[0032] Preferably, the venom is from a snake of a family selected from Atractaspididae (atractaspidids), Colubridae (colubrids) Elapidae (elapids), Hydrophidae (sea snakes) and Viperidae (viperids). For example, the venom may be viper snake venom (e.g. from the Russell’s viper). Viper snakes cause around 60% of overall snakebite incidents globally and cause significant muscle damage due to the venom’s effect in affecting the blood supply to the tissue, destroying the ECM and damaging the muscle fibres.

[0033] For the subject, the present invention enables limbs and other significant portions of the body to be saved from the effects of a snakebite. For example, the invention can prevent venom-induced systemic envenomation effects such as neurotoxicity, haemotoxicity, nephrotoxicity,coagulotoxicity and cytotoxicity as well as other effects of envenomation that are induced by PLA2 and metalloproteases. For the wider population, there are significant socioeconomic benefits from reduced long-term healthcare requirements and enhanced activity of the population in regions that are significantly afflicted by envenomation from snakebites.

[0034] It is thought that, following envenomation by a snakebite, phospholipase A2, metalloproteases and 3FTXs in venom cause myotoxicity, weakening the ECM and thereby causing fibrosis.

[0035] Nilotinib, a tyrosine kinase inhibitor, has been reported to reduce fibrosis following notexin (a 3FTX)-induced acute muscle damage by promoting the apoptosis of fibro-adipogenic progenitor cells (FAPs) through blocking the tumour necrosis factor pi (TGF-pi)-induced p38 kinase activation in these cells. Tyrosine kinase inhibitors such as nilotinib have previously found application in the treatment of chronic myeloid leukaemia (Lemos, D., et al., Nat Med 21, 786-794 (2015). doi:10.1038 / nm.3869). Notexin is found in the venom of snakes of the family Elapidae (elapids, such as cobras). However, notexin differs significantly from the whole venom, which is a mixture of various toxins including other components, such as metalloproteases, that affect muscle and induce fibrosis. 3FTX causes a small amount of necrosis; however, snake venom typically destroys muscle ECM, causing a massive inflammatory response and far more significant amounts of necrosis.

[0036] Alternative anti-fibrotic drugs, such as soluble activin receptor type IIB, have been previously investigated for use in the treatment of envenomation (Sonavane, M. et al., Toxins 2025, 17, 59; https: / / doi.org / 10.3390 / toxinsl7020059). Soluble activin receptor type IIB is a large protein that counteracts the actions of myostatin and activin to promote muscle regeneration. However, this large molecule possesses numerous disadvantages, such as the inability to be used in oral formulations, high production costs and unknown side effects. It can only be taken via parenteral routes. Therefore, the use of “small molecule” compounds, such as nilotinib, to tackle muscle damage and fibrosis provides more benefits in tackling this issue. In addition, owing to the different mechanism of action of soluble activin receptor type IIB compared to tyrosine kinase inhibitors such as nilotinib, the results of the present invention remain surprising. Furthermore, the effects of such previous studies have not been as significant as those reported herein.

[0037] US 2021 / 0260029 Al describes the use of a PLA2 inhibitor selected from the group consisting of varespladib, methylvarespladib, or a pharmaceutically acceptable salt thereof and at least one additional agent selected from the group consisting of a metalloproteinase inhibitor, a snake antivenom or a mixture thereof for inhibiting, delaying and / or ameliorating the effects of snake envenomation. The disclosure of US 2021 / 0260029 Al focusses on the simple neutralisation ofPLA2, and may not have a significant effect on preventing the effects of local envenomation. However, the claimed invention can prevent, treat, inhibit, delay and / or ameliorate the effects of local envenomation. This can be achieved by simultaneously inhibiting toxins present in venom and promoting tissue regeneration. As discussed above, the claimed invention provides significant and surprising results.

[0038] The components of the present invention can be used to prevent, treat, inhibit, delay and / or ameliorate the effects of an envenomation, especially by snake venom.

[0039] According to a third aspect, the claimed invention provides a PLA2 inhibitor (e.g. varespladib) for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprises administering a tyrosine kinase inhibitor (e.g. nilotinib), and optionally administering a matrix metalloprotease inhibitor (e.g. marimastat).

[0040] According to a fourth aspect the claimed invention provides a matrix metalloprotease inhibitor (e.g. marimastat) for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprises administering a tyrosine kinase inhibitor (e.g. nilotinib), and optionally administering a PLA2 inhibitor (e.g. varespladib).

[0041] According to a fifth aspect the claimed invention provides a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor (e.g. nilotinib). The method may further comprise administering to the subject a PLA2 inhibitor (e.g. varespladib) and / or administering to the subject a matrix metalloprotease inhibitor (e.g. marimastat).

[0042] According to a sixth aspect the claimed invention provides a PLA2 inhibitor (e.g. varespladib) for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor (e.g. nilotinib), and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a matrix metalloprotease inhibitor (e.g. marimastat).

[0043] According to a seventh aspect the claimed invention provides a matrix metalloprotease inhibitor (e.g. marimastat) for use in the manufacture of a medicament for the prevention, treatment,inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor (e.g. nilotinib), and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a PLA2 inhibitor (e.g. varespladib).

[0044] According to an eighth aspect the claimed invention provides a tyrosine kinase inhibitor (e.g. nilotinib) for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject. The prevention, treatment, inhibition, delay and / or amelioration may further comprise the administration of a matrix metalloprotease inhibitor (e.g. marimastat) and / or the administration of a PLA2 inhibitor (e.g. varespladib).

[0045] According to a ninth aspect the claimed invention comprises a pharmaceutical composition comprising a tyrosine kinase inhibitor (e.g. nilotinib) and either or both of a PLA2 inhibitor (e.g. varespladib) and a matrix metalloprotease inhibitor (e.g. marimastat).

[0046] The present disclosure includes the subject-matter of the following clauses:

[0047] 1. A tyrosine kinase inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject.

[0048] 2. The tyrosine kinase inhibitor for use of clause 1, wherein the tyrosine kinase inhibitor is selected from the list consisting of nilotinib, Acalabrutinib, Adavosertib, Afatinib, Alectinib, Anlotinib, Apatinib, Asciminib, Aumolertinib, Avapritinib, Axitinib, Bafetinib, Bosutinib, Cabozantinib, Canertinib, cetuximab, Crenolanib, Dacomitinib, Damnacanthal, Dasatinib, Entospletinib, Entrectinib, Erlotinib, Foretinib, Fostamatinib, Fruquintinib, Futibatinib, Gefitinib, Gilteritinib, Glesatinib, HS-10365, Ibrutinib, Icotinib, Idelalisib, IDRX-42, Imatinib, Infigratinib, Ivosidenib, Lapatinib, Larotrectinib, Lazertinib, Lenvatinib, Linifanib, Lorlatinib, Masitinib, Midostaurin, Mirdametinib, Mobocertinib, Motesanib, Mubritinib, Nemtabrutinib, Nilotinib, Neratinib, Netarsudil, Nimotuzumab, Nintedanib, Olverembatinib, panitumumab, Pazopanib, Pirtobrutinib, Ponatinib, Radotinib, Regorafenib, Remibrutinib, Repotrectinib, Ropsacitinib, Savolitinib, Selpercatinib, Sorafenib, Sitravatinib, Sunitinib, Sunvozertinib, T790M, Tesevatinib, Tolebrutinib, V600E, Vatalanib, vandetanib and Zasocitinib.

[0049] 3. The tyrosine kinase inhibitor for use of clause 2, wherein the tyrosine kinase inhibitor is nilotinib.

[0050] 4. The tyrosine kinase inhibitor for use of any preceding clause, wherein the method further comprises administering a phospholipase A2 (PLA2) inhibitor.5. The tyrosine kinase inhibitor for use of clause 4, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, darapladib, manoalide, U-73122, Quinacrine, Quercetin, Chlorpromazine, Aristolochic Acid, Cinnamycin, MJ33, ETYA, N-(p-Amylcinnamoyl) anthranilic acid, ML349 and arachidonyl trifluoromethyl ketone.

[0051] 6. The tyrosine kinase inhibitor for use of clause 5, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, and darapladib.

[0052] 7. The tyrosine kinase inhibitor for use of clause 6, wherein the PLA2 inhibitor is varespladib.

[0053] 8. The tyrosine kinase inhibitor for use of any preceding clause, wherein the method further comprises administering a matrix metalloprotease inhibitor.

[0054] 9. The tyrosine kinase inhibitor for use of clause 8, wherein the matrix metalloprotease inhibitor is selected from the list consisting of marimastat, batimastat (BB-94), prinomastat (AG3340), tanomastat (BAY 12-9566), CGS-27023 (CAS 169799-04-6), ilomastat, doxycycline hyclate, TAPI-1 (CAS 163847-77-6), actinonin, NNGH (CAS 161314-17-6), tissue inhibitors of metalloproteinases, squalamine, genistein, nobiletin, myricetin, curcumin, xanthorhizzol, theaflavin, resveratrol, actinonin, matlystatin B, nicotinamide, betulinic acid, glycyrrhetinic acid, catechin, bryostatins, and tetracyclines.

[0055] 10. The tyrosine kinase inhibitor for use of clause 9, wherein the matrix metalloprotease inhibitor is marimastat or prinomastat.

[0056] 11. The tyrosine kinase inhibitor for use of clause 10, wherein the matrix metalloprotease inhibitor is marimastat.

[0057] 12. The tyrosine kinase inhibitor for use of any one of clauses 8 to 11, wherein the matrix metalloprotease inhibitor is administered for a duration of from 2 days to 7 days.

[0058] 13. The tyrosine kinase inhibitor for use of any one of clauses 1 to 3, wherein the method further comprises administering a PLA2 inhibitor and administering a matrix metalloprotease inhibitor.

[0059] 14. The tyrosine kinase inhibitor for use of clause 13, wherein the tyrosine kinase inhibitor is nilotinib, the matrix metalloprotease inhibitor is marimastat, and the PLA2 inhibitor is varespladib.

[0060] 15. The tyrosine kinase inhibitor for use of any preceding clause, wherein the venom was snake venom.

[0061] 16. The tyrosine kinase inhibitor for use of clause 15, wherein the snake is of the Viperidae family.

[0062] 17. The tyrosine kinase inhibitor for use of any preceding clause, wherein the method further comprises administering an antivenom.

[0063] 18. A kit comprising a tyrosine kinase inhibitor, and either or both of a PLA2 inhibitor and a matrix metalloprotease inhibitor.

[0064] 19. A PLA2 inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprisesadministering a tyrosine kinase inhibitor, and optionally administering a matrix metalloprotease inhibitor.

[0065] 20. A matrix metalloprotease inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprises administering a tyrosine kinase inhibitor, and optionally administering a PLA2 inhibitor.

[0066] 21. A method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor, wherein optionally the method further comprises administering to the subject a PLA2 inhibitor and / or administering to the subject a matrix metalloprotease inhibitor.

[0067] 22. A PLA2 inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor, and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a matrix metalloprotease inhibitor.

[0068] 23. A matrix metalloprotease inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor, and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a PLA2 inhibitor.

[0069] 24. A tyrosine kinase inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein optionally the treatment further comprises the administration of a matrix metalloprotease inhibitor and / or the administration of a PLA2 inhibitor.

[0070] 25. A pharmaceutical composition comprising a tyrosine kinase inhibitor and either or both of a PLA2 inhibitor and a matrix metalloprotease inhibitor.

[0071] 26. A pharmaceutical composition comprising: a tyrosine kinase inhibitor, and at least one of a phospholipase A2 (PLA2) inhibitor and a matrix metalloprotease (MMP) inhibitor.

[0072] 27. The composition as disclosed in clause 26, wherein the tyrosine kinase inhibitor is selected from the list consisting of nilotinib, Acalabrutinib, Adavosertib, Afatinib, Alectinib, Anlotinib, Apatinib, Aumolertinib, Avapritinib, Axitinib, Bosutinib, Cabozantinib, Canertinib, cetuximab, Crenolanib, Dacomitinib, Damnacanthal, Dasatinib, Entospletinib, Entrectinib, Erlotinib, Foretinib, Fostamatinib, Fruquintinib, Futibatinib, Gefitinib, Gilteritinib, Glesatinib, HS-10365, Ibrutinib, Icotinib, Idelalisib, IDRX-42, Imatinib, Infigratinib, Ivosidenib, Lapatinib, Larotrectinib, Lazertinib, Lenvatinib, Linifanib, Lorlatinib, Masitinib, Midostaurin, Mirdametinib, Mobocertinib, Motesanib, Mubritinib, Nemtabrutinib, Nilotinib, Neratinib, Netarsudil, Nimotuzumab, Nintedanib, Olverembatinib, panitumumab, Pazopanib, Pirtobrutinib,Ponatinib, Radotinib, Regorafenib, Remibrutinib, Repotrectinib, Ropsacitinib, Savolitinib, Selpercatinib, Sorafenib, Sitravatinib, Sunitinib, Sunvozertinib, T790M, Tesevatinib, Tolebrutinib, V600E, Vatalanib, vandetanib and Zasocitinib.

[0073] 28. The composition as disclosed in clause 27, wherein the tyrosine kinase inhibitor is nilotinib.

[0074] 29. The composition as disclosed in clause 26, wherein the composition comprises a phospholipase A2 (PLA2) inhibitor.

[0075] 30. The composition as disclosed in clause 29, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, darapladib, manoalide, U-73122, Quinacrine, Quercetin, Chlorpromazine, Aristolochic Acid, Cinnamycin, MJ33, ETYA, N-(p-Amylcinnamoyl) anthranilic acid, ML349 and arachidonyl trifluoromethyl ketone.

[0076] 31. The composition as disclosed in clause 30, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, and darapladib.

[0077] 32. The composition as disclosed in clause 31, wherein the PLA2 inhibitor is varespladib.

[0078] 33. The composition as disclosed in any one of clauses 26 to 32, wherein the composition or the kit comprises a matrix metalloprotease inhibitor.

[0079] 34. The composition as disclosed in clause 33, wherein the matrix metalloprotease inhibitor is selected from the list consisting of marimastat, batimastat (BB-94), prinomastat (AG3340), tanomastat (BAY 12-9566), CGS-27023 (CAS 169799-04-6), ilomastat, doxycycline hyclate, TAPI-1 (CAS 163847-77-6), actinonin, NNGH (CAS 161314-17-6), tissue inhibitors of metalloproteinases, squalamine, genistein, nobiletin, myricetin, curcumin, xanthorhizzol, theaflavin, resveratrol, actinonin, matlystatin B, nicotinamide, betulinic acid, glycyrrhetinic acid, catechin, bryostatins, and tetracyclines.

[0080] 35. The composition as disclosed in clause 34, wherein the matrix metalloprotease inhibitor is marimastat or prinomastat.

[0081] 36. The composition as disclosed in clause 35, wherein the matrix metalloprotease inhibitor is marimastat.

[0082] 37. The composition as disclosed in clauses 33 to 36, wherein the matrix metalloprotease inhibitor is administered for a duration of from 2 days to 7 days.

[0083] 38. The composition as disclosed in clauses 26 to 28, wherein the composition comprises a PLA2 inhibitor and a matrix metalloprotease inhibitor.

[0084] 39. The composition as disclosed in clause 38, wherein the tyrosine kinase inhibitor is nilotinib, the matrix metalloprotease inhibitor is marimastat, and the PLA2 inhibitor is varespladib.

[0085] 40. The composition as disclosed in clause 26, wherein the composition further comprises an antivenom.41. A kit comprising a tyrosine kinase inhibitor, and either or both of a PLA2 inhibitor and a matrix metalloprotease inhibitor.

[0086] 42. The kit as disclosed in clause 41, wherein the tyrosine kinase inhibitor is nilotinib, the PLA2 inhibitor is varespladib, and the matrix metalloprotease inhibitor is marimastat.

[0087] 43. The kit as disclosed in clause 41 or 42, further comprising an antivenom.

[0088] Brief Description of the Drawings

[0089] Embodiments of the present invention will now be described by way of example with reference to the accompanying drawings, in which:

[0090] Figure 1 shows the percentage weight loss of the TA muscle of mice in the treated groups: Russell’s viper venom (DR); DR and varespladib (V); DR and marimastat (M);

[0091] DR+V+M; DR and antivenom (AV); DR, AV and V; DR, AV and M; DR+AV+V+M; and negative control;

[0092] Figure 2 shows the percentage picrosirius red positive area of mouse muscle treated with: Russell’s viper venom (DR); DR and varespladib (V); DR and marimastat (M); DR+V+M; DR and antivenom (AV); DR, AV and V; DR, AV and M; DR+AV+V+M; and negative control;

[0093] Figure 3 shows the percentage weight loss of the TA muscle of mice (A), the percentage picrosirius red positive area of mouse muscle (B), and the percentage collagen deposition (C) in the muscle of mice treated by cardiotoxin (CTX); and CTX and marimastat (M);

[0094] Figure 4 shows the percentage weight loss of the TA muscle of mice (A), the percentage picrosirius red positive area (B) of mouse muscle, and the percentage damaged area (C) in muscle of mice treated by: Russell’s viper venom (DR); DR and nilotinib (N); DR, N and varespladib (V); and DR+N+V+M;

[0095] Figure 5 shows the percentage laminin-positive area (A) and the percentage dystrophinpositive area (B) of muscle tissue treated by: Russell’s viper venom (DR); DR and nilotinib (N); DR, N and varespladib (V); and DR+N+V+M;

[0096] Figure 6 shows the percentage immunoglobulin G positive area (A), the level of cluster of differentiation 31 (B), and the percentage platelet-derived growth factor receptor a area (C) for muscle tissue treated by: Russell’s viper venom (DR); DR and nilotinib (N); DR, N and varespladib (V); and DR+N+V+M;

[0097] Figures 7-77 show the percentage survival of mice administered various snake venoms before being administered a single dose containing N+V+M;

[0098] Figure 78 shows the percentage survival of mice administered Bungarus caeruleus venom before being administered two doses of N+V+M;Figure 79 shows the percentage survival of mice administered Bungarus caeruleus venom before being administered four doses of N+V+M;

[0099] - Figure 80 shows photographs illustrating the reduction in haemorrhage in mice administered by various snake venoms before being administered a N+V+M; and

[0100] Figure 81 shows photographs illustrating the extent of haemorrhage in mice administered by various snake venoms before being administered a N+V+M, Ibrutinib+V+M, or Imatinib+V+M.

[0101] Detailed Description of the Invention

[0102] The term “about” may mean + / -20%, such as + / -10%, or + / -5%.

[0103] The effects of envenomation in a subject may include muscle fibrosis; tissue (e.g. muscle) necrosis, damage and / or loss; increased levels of markers associated with cellular and tissue repair (e.g. IgG, CD31 and / or PDGFRa); neurotoxicity; haemotoxicity; nephrotoxicity; cytotoxicity and / or death.

[0104] The envenomation may be caused by contact with a venom or poison. In particular, envenomation may be caused by the injection of venom including from an animal (invertebrate or vertebrate). Most frequently, envenomation is the result of a snakebite. The venom may be from any venomous animal (e.g. snake). Venomous snakes may be of a family selected from Atractaspididae (atractaspidids), Colubridae (colubrids) Elapidae (elapids), Hydrophidae (sea snakes) and Viperidae (viperids), all of which include venomous snakes. Preferably the venom is from a snake of the Viperidae (viperids) family, i.e. a viper.

[0105] The venom may be derived from a venomous snake belonging to the order Squamata, suborder Serpentes, including a snake from the families Elapidae, Viperidae, Atractaspididae, and Colubridae, or a related venomous snake lineage. The venomous snake may belong to the family Elapidae, such as a species of a genus selected from the list consisting of Naja, Bungarus, Dendroaspis, Micrurus, Micruroides, Ophiophagus, Aspidelaps, Hemachatus, Hydrophis, Laticauda, Notechis, Oxyuranus, Pseudechis, Pseudonaja and Acanthophis. The venomous snake may belong to the family Viperidae, such as a species of a genus selected from the list consisting of Vipera, Daboia, Echis, Bitis, Cerastes, Macrovipera, Montivipera, Proatheris, Atheris, Causus, Bothrops, Crotalus, Lachesis, Trimeresurus, Protobothrops, Gloydius, Hypnale and Calloselasma. The venomous snake may belong to the family Atractaspididae, such as a species of a genus selected from the list consisting of Atractaspis, Homoroselaps, Macrelaps and Aparallactus. The venomous snake may belong to a venomous lineage within the family Colubridae or related rear-fanged snake groups, such as a species of a genus selected from thelist consisting of Dispholidus, Thelotornis, Boiga, Rhabdophis, Telescopus, Thamnodynastes, and Philodryas. The venom may be derived from any venomous or medically significant snake species capable of delivering venom to a human or an animal, including species not explicitly listed above, newly described species, or taxonomically revised genera within the aforementioned families.

[0106] The venom may be from a snake selected from the list consisting of: Bungariis caeruleiis (Common krait), Naja naja (Indian cobra), Echis carinatus (Saw-scaled viper), Daboia russelii (Russell's viper), Bitis arietans (Puff adder), Crotalus atrox (Western diamondback rattlesnake), Bothrops atrox (Common lancehead), Vipera berus (European adder), Micruriis obscur s (Coral snake), Oxyranus scutellatus (Coastal taipan), Dendroaspis polylepis (Black mamba), Acanthopis rugosus (Death adder), Agkistrodon laticinctus (Broad-banded copperhead), Agkistrodon contortrix (Copperhead), Agkistrodon bilineatus (Cantil viper), Agkistrodon piscivorus (Cottonmouth), Agkistrodon taylori (Taylor's cantil), Atractaspis fallax (Peters' burrowing asp), Agkistrodon leucostoma (Western cottonmouth), Bitis rhinoceros (Gaboon viper), Bitis nasicornis (Butterfly viper), Bothrops alternatus (Crossed pit viper), Bothrops atrox from Suriname (Lancehead), Bothrops atrox from Columbia (Lancehead), Bothrops asper (Fer-de-lance), Bothrops atrox from Guyana (Lancehead), Bungarus Candidas (Malayan krait), Bungarus fasciatus (Banded cobra), Bothrops moojeni (Brazilian lancehead), Bothrops jararacussu (Jararacussu), Calloselasma rhodostoma (Malayan pit viper), Crotalus scutulatus scutulatus from Arizona (Mohave rattlesnake), Craspedocephalus puniceus (Flat-nosed pit viper), Crotalus horridus (Timber rattlesnake), Crotalus scutulatus scutulatus from Texas (Mohave rattlesnake), Crotalus viridis viridis (Prairie rattlesnake), Deinagkistrodon acutus (Chinese moccasin), Echis leucogaster (White-bellied carpet viper), Echis pyramidum (Northeast African carpet viper), Dendroaspis viridis (Western green mamba), Echis ocellatus (West African carpet viper), Hypnale hypnale (Hump-nosed pit viper), Lachesis muta (Bushmaster), Macrovipera lebetinus tauranica (Lebetine viper), Echis sochureki (Sochurek's saw-scaled viper), Naja guineensis (Black forest cobra), Naja annulata (Banded water cobra), Montivipera xanthina (Rock viper), Metlapilcoatlus mexicanum (Central American jumping pit viper), Naja nigricollis (Black-necked spitting cobra), Naja haje (Egyptian cobra), Naja nana (Dwarf water viper), Naja nivea (Cape viper), Naja savannula (West African banded cobra), Naja subfulva (Brown forest cobra), Naja pallida (Red spitting cobra), Ovophis okinavensis (Hime habu), Oxyuranus scutellatus scutellatus (Coastal taipan), Oxyuranus microlepidotus (Inland taipan), Oxyuranus scutellatus canni (Coastal taipan), Protobothrops elegans (Elegant pit viper), Trimeresurus insularis (Indonesian pit viper), Pseudechis colletti (Collett's black snake), Macrovipera mauritanica (Moorish viper), Vipera ammodytes (Horned viper), Trimeresurus purpureomaculatus (Mongrove pit viper), Naja annulifera (Snouted cobra), andNaja mossambica (Mozambique spitting cobra). The venom may be from a snake selected from purple-glossed snake, centipede eater, burrowing asp, Revoil's short snake, Chilorhinophis, Hypoptophis, Homoroselaps, Macrelaps, Micrelaps, boomslang, spitting cobras, green mamba, black mamba, Keelback snake, sea snake, taipan, brown snake, coral snake, krait, death adder, tiger snake, mamba, king cobra, cobra, any true vipers (e.g. Russell's viper), saw-scaled viper, puff adder, carpet viper, horned viper, and any pit vipers (including rattlesnake, lancehead, copperhead, hump-nosed pit viper, Malabar pit viper and cottonmouth).

[0107] Preferably the venom is from a snake selected from the list consisting of: Naja naja, Echis carinatus, Daboia russelii, Bitis arietans, Crotalus atrox, Bothrops atrox, Vipera berus, Oxyranus scutellatus, Agkistrodon laticinctus, Agkistrodon contortrix, Agkistrodon bilineatus, Agkistrodon piscivorus, Agkistrodon taylori, Atractaspis fallax, Agkistrodon leucostoma, Bitis rhinoceros, Bitis nasicornis, Bothrops atrox from Columbia, Bothrops asper, Bothrops atrox from Guyana, Bungarus fasciatus, Bothrops jararacussu, Calloselasma rhodostoma, Crotalus scutulatus scutulatus from Arizona, Crotalus horridus, Crotalus scutulatus scutulatus from Texas, Crotalus viridis viridis, Echis pyramidum, Hypnale hypnale, Lachesis muta, Macrovipera lebetinus tauranica, Naja guineensis, Montivipera xanthina, Naja nigricollis, Naja haje, Naja savannula, Naja pallida, Ovophis okinavensis, Oxyuranus scutellatus scutellatus, Oxyuranus microlepidotus, Oxyuranus scutellatus canni, Protobothrops elegans, Pseudechis colletti, Vipera ammodytes, Trimeresurus purpureomaculatus , and Naja mossambica. Preferably, the venom is from a snake selected from the Indian cobra, common krait, Russell's viper, and saw-scaled viper.

[0108] More preferably the venom is from a snake selected from the list consisting of: Daboia russelii, Bitis arietans, Crotalus atrox, Bothrops atrox, Vipera berus, Oxyranus scutellatus, Agkistrodon laticinctus, Agkistrodon bilineatus, Agkistrodon piscivorus, Agkistrodon taylori, Atractaspis fallax, Agkistrodon leucostoma, Bitis rhinoceros, Bitis nasicornis, Bothrops atrox from Columbia, Bungarus fasciatus, Calloselasma rhodostoma, Crotalus scutulatus scutulatus from Arizona, Crotalus horridus, Crotalus scutulatus scutulatus from Texas, Lachesis muta, Ovophis okinavensis, Oxyuranus scutellatus scutellatus, Oxyuranus microlepidotus, Oxyuranus scutellatus canni, Protobothrops elegans, Pseudechis colletti, Vipera ammodytes, Trimeresurus purpureomaculatus , and Naja mossambica.

[0109] Yet more preferably the venom is from a snake selected from the list consisting of: Bitis arietans, Vipera berus, Agkistrodon laticinctus, Agkistrodon bilineatus, Agkistrodon taylori, Agkistrodon leucostoma, Bitis nasicornis, Bothrops atrox, Crotalus horridus, Lachesis muta, Oxyuranus scutellatus scutellatus, and Vipera ammodytes.The PLA2 inhibitor, the tyrosine kinase inhibitor and the matrix metalloprotease inhibitor may each be referred to as a component of the invention.

[0110] The PLA2 inhibitor may be selected from the list consisting of Varespladib (LY315920), Varespladib methyl (LY333013), Darapladib, LY311727, Pyrrophenone, Quinacrine, Bromoenol lactone (BEL), AACOCF3 (arachidonyl trifluoromethyl ketone), MJ33, ONO-RS-082, OPC-6535, OPC-29030, Scalaradial, Aristolochic acid, S3319, and S5920. The PLA2 inhibitor may be a secreted PLA2 inhibitor, a cytosolic PLA2 inhibitor, a calcium-independent PLA2 inhibitor, and / or a lipoprotein-associated PLA2 inhibitor.

[0111] The phospholipase A2 (PLA2) inhibitor may be selected from the list consisting of varespladib, methyl varespladib, darapladib, manoalide, U-73122 (CAS 112648-68-7), Quinacrine, Quercetin, Chlorpromazine, Aristolochic Acid, Cinnamycin, MJ33 (CAS 1135306-36-3), ETYA (CAS 1191-85-1), N-(p-Amylcinnamoyl) anthranilic acid, ML349 (CAS 890819-86-0) and arachidonyl trifluoromethyl ketone. Preferably the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, and darapladib. Most preferably the PLA2 inhibitor is varespladib. The PLA2 inhibitor may be a pharmaceutically acceptable salt, ester, prodrug, stereoisomer, metabolite, polymorph, derivative, or structural analogue of any compound listed above.

[0112] The matrix metalloprotease inhibitor may be selected from the list consisting of marimastat, batimastat, prinomastat, rebimastat, ilomastat, doxycycline, minocycline, actinonin, CGS27023A, PD-166793, PG-116800, ND-336, SB-3CT, FN-439, Ro-28-2653, Ro-31-9790, Ro-32-3555, COL-3, and aderbasib. The matrix metalloprotease inhibitor may be selected from the list consisting of marimastat, batimastat (BB-94), prinomastat (AG3340), tanomastat (BAY 12-9566), CGS-27023 (CAS 169799-04-6), ilomastat, doxycycline hyclate, TAPI-1 (CAS 163847-77-6), actinonin, NNGH (CAS 161314-17-6), tissue inhibitors of metalloproteinases (TIMPs, e.g. TIMP-1, TIMP-2, TIMP-3, TIMP-4), squalamine, genistein, nobiletin, myricetin, curcumin, xanthorhizzol, theaflavin, resveratrol, actinonin, matlystatin B, nicotinamide, betulinic acid, glycyrrhetinic acid, catechin, bryostatins (e.g. bryostatin-1), tetracyclines (e.g. Doxycycline and minocycline) and metal chelators (e.g. unithiol, ethylenediaminetetraacetic acid (EDTA), diethylene triamine pentaacetic acid (DTPA), N,N'-bis(2-aminoethyl)ethylenediamine-N,N'-diacetic acid (TPEN), l,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), IDHA (imidodisuccinic acid), ethylenediamine-N,N’-disuccinic acid (EDDS), ethylenediamine-N(o-hydroxyphenylacetic)-N’(p-hydroxyphenylacetic) acid (o,p-EDDHA), ethylenediamine-N,N’bis(o-hydroxyphenyl)acetic acid (0,0-EDDHA), and ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)). Unithiol is a preferred metal chelator. Metal chelators such as those disclosed above chelate Zn ions that are necessary formetalloprotease activity, thereby indirectly inhibiting the function of matrix metalloproteases. Preferably the matrix metalloprotease inhibitor is selected from marimastat and prinomastat. Most preferably the matrix metalloprotease inhibitor is marimastat. The matrix metalloprotease inhibitor may be a pharmaceutically acceptable salt, ester, prodrug, stereoisomer, metabolite, polymorph, derivative, or structural analogue of any compound listed above.

[0113] The tyrosine kinase inhibitor may be a first-generation tyrosine kinase inhibitor, a second-generation tyrosine kinase inhibitor and / or a Bcr-Abl tyrosine kinase inhibitor. The tyrosine kinase inhibitor may be selected from the list consisting of Abemaciclib, Acalabrutinib, Afatinib, Alectinib, Alpelisib, Anlotinib, Asciminib, Axitinib, Baricitinib, Belvarafenib, Bemcentinib, Binimetinib, Bosutinib, Brigatinib, Cabozantinib, Capmatinib, Ceritinib, Cobimetinib, Copanlisib, Crizotinib, Dabrafenib, Dacomitinib, Dasatinib, Delgocitinib, Duvelisib, Erdafitinib, Erlotinib, Fedratinib, Fostamatinib, Fruquintinib, Futibatinib, Gefitinib, Gilteritinib, Glasdegib, Ibrutinib, Idelalisib, Imatinib, Infigratinib, Eapatinib, Earotrectinib, Lenvatinib, Linsitinib, Lorlatinib, Masitinib, Midostaurin, Mobocertinib, Momelotinib, Neratinib, Nilotinib, Nintedanib, Olverembatinib, Osimertinib, Palbociclib, Pazopanib, Pemigatinib, Pexidartinib, Ponatinib, Pralsetinib, Pirtobrutinib, Quizartinib, Regorafenib, Ribociclib, Ripretinib, Ruxolitinib, Saracatinib, Selpercatinib, Sitravatinib, Sorafenib, Sunitinib, Tepotinib, Tivozanib, Tofacitinib, Trametinib, Tucatinib, Upadacitinib, Vandetanib, Vemurafenib, and Zanubrutinib. The tyrosine kinase inhibitor may be a multi-kinase inhibitor targeting ABL, SRC, VEGFR, PDGFR, EGFR, ALK, RET, JAK, FGFR, KIT, FLT3, and / or MET signalling pathways. The tyrosine kinase inhibitor may be selected from the list consisting of Acalabrutinib, Adavosertib, Afatinib, Alectinib, Anlotinib, Apatinib, Aumolertinib, Avapritinib, Axitinib, Bosutinib, Cabozantinib, Canertinib, cetuximab, Crenolanib, Dacomitinib, Damnacanthal, Dasatinib, Entospletinib, Entrectinib, Erlotinib, Foretinib, Fostamatinib, Fruquintinib, Futibatinib, Gefitinib, Gilteritinib, Glesatinib, HS-10365, Ibrutinib, Icotinib, Idelalisib, IDRX-42, Imatinib, Infigratinib, Ivosidenib, Lapatinib, Larotrectinib, Lazertinib, Lenvatinib, Linifanib, Lorlatinib, Masitinib, Midostaurin, Mirdametinib, Mobocertinib, Motesanib, Mubritinib, Nemtabrutinib, Nilotinib, Neratinib, Netarsudil, Nimotuzumab, Nintedanib, Olverembatinib, panitumumab, Pazopanib, Pirtobrutinib, Ponatinib, Radotinib, Regorafenib, Remibrutinib, Repotrectinib, Ropsacitinib, Savolitinib, Selpercatinib, Sorafenib, Sitravatinib, Sunitinib, Sunvozertinib, T790M, Tesevatinib, Tolebrutinib, V600E, Vatalanib, vandetanib and Zasocitinib. The tyrosine kinase inhibitor may additionally be asciminib or bafetinib. Preferably the tyrosine kinase inhibitor is a Bcr-Abl tyrosine kinase inhibitors; examples of Bcr-Abl tyrosine kinase inhibitors include asciminib, imatinib, nilotinib, dasatinib, bosutinib, ponatinib and bafetinib. More preferably the tyrosine kinase inhibitor is a second generation Bcr-Abl tyrosine kinase inhibitor, such as nilotinib or dasatinib. Most preferably the tyrosine kinase inhibitor is nilotinib. Thetyrosine kinase inhibitor may be a pharmaceutically acceptable salt, ester, prodrug, stereoisomer, metabolite, polymorph, derivative, or structural analogue of any compound listed above.

[0114] Compositions

[0115] A pharmaceutical composition (e.g. formulation) may comprise one or more of the components of the invention together with a pharmaceutically acceptable carrier, adjuvant, excipient, diluent, filler, buffer, stabiliser, preservative, lubricant or any other related materials.

[0116] To prepare the pharmaceutical compositions of this invention, an effective amount of the or each component of the invention, as the active ingredient(s), can be combined in intimate admixture with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration. The pharmaceutical compositions can be in any form suitable for administration by inhalation or gastric tube, or oral, parenteral (including intravenous, intramuscular and intraperitoneal), topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, subcutaneous or transdermal (e.g. using a patch, cream, or autoinjector (such as an EpiPen®-like autoinjector)) administration.

[0117] The components of the invention may be administered by oral administration (e.g. by tablet or capsule), inhalation (e.g. using an inhaler), gastric tube (nasogastric tube or orogastric tube), transdermal administration (e.g. using an autoinjector or transdermal patch), or injection. Preferably the components of the invention are for oral administration. Preferably the components of the invention are provided as three separate tablets (one for each component).

[0118] The carrier may be water (e.g. water for injection), saline or a pH buffer (e.g. citrate, phosphate, acetate and / or sodium bicarbonate). Preferably the pH of the composition is from 5.5 to 9.0, or 6.0 to 8.0 (e.g. phosphate buffer), more preferably from 6.5 to 8.0.

[0119] Solid dosage forms for oral administration include capsules, tablets (including dispersable tablets), chews, lozenges, pills, powders, and multi-particulate preparations (granules). In such solid dosage forms, one or more of the components of the invention, can be admixed with at least one inert excipient, diluent, or carrier. Suitable excipients, diluents or carriers include materials such as sodium citrate or dicalcium phosphate and / or (a) one or more fillers or extenders (e.g., microcrystalline cellulose) starches, lactose, sucrose, mannitol, silicic acid, xylitol, sorbitol, dextrose, calcium hydrogen phosphate, dextrin, alpha-cyclodextrin, beta-cyclodextrin, polyethylene glycol, medium chain fatty acids, titanium oxide, magnesium oxide, aluminium oxide); (b) one or more binders (e.g., carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatine, gum Arabic, ethyl cellulose,polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, alginates, polyvinylpyrrolidone, sucrose, acacia); (c) one or more humectants (e.g., glycerol); (d) one or more disintegrating agents (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, sodium carbonate, sodium lauryl sulphate, sodium starch glycolate, cross-linked polyvinyl pyrrolidone, croscarmellose sodium A-type, polyacrilin potassium (an ion exchange resin)); (e) one or more solution retarders (e.g., paraffin); (f) one or more absorption accelerators (e.g., quaternary ammonium compounds); (g) one or more wetting agents (e.g., cetyl alcohol, glycerol monostearate,); (h) one or more adsorbents (e.g., kaolin, bentonite); and / or (i) one or more lubricants (e.g., talc, calcium stearate, magnesium stearate, stearic acid, polyoxyl stearate, cetanol, talc, hydrogenated castor oil, sucrose esters of fatty acid, dimethylpolysiloxane, microcrystalline wax, yellow beeswax, white beeswax, solid polyethylene glycols, sodium lauryl sulfate). In the case of capsules and tablets, the dosage forms may also comprise buffering agents.

[0120] Solid compositions may also be used as fillers in soft or hard filled gelatine capsules using such excipients as lactose, as well as high molecular weight polyethylene glycols. Solid dosage forms such as tablets, dragees, capsules, and granules may be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may also contain opacifying agents, and can also be of such composition that they release the compound of the present disclosure and / or the additional pharmaceutical agent in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The component or components may also be in micro- encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0121] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. In addition to the compound of the present disclosure or the combination, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, sesame seed oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, and fatty acid esters of sorbitan, or mixtures of these substances. Besides such inert diluents, the composition may also include excipients, such as wetting agents, emulsifying and suspending agents, sweetening, flavouring, and perfuming agents.

[0122] Oral liquid forms of the compounds of the disclosure or combinations include solutions, wherein the active compound is fully dissolved. Examples of solvents include all pharmaceuticallyprecedented solvents suitable for oral administration, particularly those in which the compounds of the disclosure show good solubility, e.g., polyethylene glycol, polypropylene glycol, edible oils, and glyceryl- and glyceride-based systems. Glyceryl- and glyceride-based systems may include glyceryl tricaprylate / caprate, medium chain triglyceride, glyceryl triacetate i.e. triacetin, medium chain mono- and diglycerides, caprylic / capric triglyceride, caprylic / capric / succinic triglyceride, propylene glycol dicaprylate / dicaprate, oleoyl macrogol-6 glycerides, glyceryl monooleate, glyceryl monooleate.

[0123] Suspensions, in addition to the compound of the present disclosure or the combination, may further comprise carriers such as suspending agents, e.g., ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, or mixtures of these substances.

[0124] Where the composition is intended for parenteral administration, it can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct delivery into a target organ or tissue by injection, infusion or other means of delivery. Preferably the composition is for intravenous administration, for example via cannula. The delivery can be by bolus injection, short-term infusion or longer-term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump.

[0125] Pharmaceutical compositions adapted for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, cosolvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels, lyophilisation protectants and combinations of agents for, inter alia, stabilising the active ingredient in a soluble form and rendering the formulation isotonic with the blood of the intended recipient. Pharmaceutical formulations for parenteral administration may also take the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents (R. G. Strickly (2004), Solubilizing Excipients in oral and injectable formulations, Pharmaceutical Research, Vol 21(2), p 201 -230). Liposomes are closed spherical vesicles composed of outer lipid bilayer membranes and an inner aqueous core and with an overall diameter of < 100 pm. Depending on the level of hydrophobicity, moderately hydrophobic drugs can be solubilized by liposomes if the drug becomes encapsulated or intercalated within the liposome. Hydrophobic drugs can also be solubilized by liposomes if the drug molecule becomes an integral part of the lipid bilayer membrane, and in this case, the hydrophobic drug is dissolved in the lipid portion of the lipid bilayer.The composition may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. The pharmaceutical composition can be prepared by lyophilising a ligand and / or complex of the invention. Lyophilisation refers to the procedure of freeze- drying a composition. Freeze-drying and lyophilisation are therefore used herein as synonyms.

[0126] Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets. Pharmaceutical compositions of the present invention for parenteral injection can also comprise pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. The compositions of the present invention may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminium monostearate and gelatine.

[0127] The pharmaceutical composition may be in a form suitable for intravenous administration, for example by injection or infusion. For intravenous administration, the solution can be dosed as is or can be injected into an infusion bag (containing a pharmaceutically acceptable excipient, such as 0.9% saline or 5% dextrose), before administration.

[0128] The present invention may employ a dosage, or dosage form, of the PLA2 inhibitor (e.g. varespladib) of about Img or higher, such as about 50mg or higher, preferably about lOOmg or higher, or about 200mg or higher, more preferably about 250mg or higher, such as about 300mg or higher, or about 400mg or higher, for example, about 450mg or higher, or about 500mg or higher, such as about 1.0g or higher, or about 1.25g or higher. The dosage, or dosage form, of the PLA2 inhibitor, may be about 2.0g or lower, such as about 1.5g or lower, preferably about1.25g (1250mg) or lower, such as about 1.0g (lOOOmg) or lower, such as about 800mg or lower, or about 600mg or lower, or about 550mg or lower, such as about 500mg or lower. The dosage, or dosage form, of the PLA2 inhibitor may be from about Img to about 2.0g, preferably from about lOOmg to about 1.0g, such as from about 300mg to about 800mg. The doses mentioned in this paragraph may be daily doses.

[0129] More preferably the dosage or dosage form of the PLA2 inhibitor is from about 250mg to about 1.25g, especially about 500mg to about 1.25g, yet more preferably about 1.0g. These doses may be daily doses.

[0130] The present invention may employ a dosage, or dosage form, of the matrix metalloprotease inhibitor (e.g. marimastat) of about Img or higher, such as about 50mg or higher, preferably about lOOmg or higher, more preferably about 200mg or higher, such as about 300mg or higher, or about 400mg or higher, for example, about 450mg or higher, or about 500mg or higher, such as about 800mg or higher, or about lOOOmg or higher. The dosage, or dosage form, of the matrix metalloprotease inhibitor, may be about 2.0g or lower, such as about 1.5g or lower, preferably about 1.0g (lOOOmg) or lower, such as about 800mg or lower, or about 600mg or lower, or about 550mg or lower, for example about 400mg or lower. The dosage, or dosage form, of the matrix metalloprotease inhibitor may be from about Img to about 2.0g, preferably from about lOOmg to about 1.0g, such as from about 300mg to about 800mg. The doses mentioned in this paragraph may be daily doses.

[0131] More preferably the dose or dosage form of the matrix metalloprotease inhibitor is from about 200 mg to about lOOOmg, especially from about 400mg to about lOOOmg, yet more preferably about 800mg. These doses may be daily doses.

[0132] The present invention may employ a dosage, or dosage form, of the tyrosine kinase inhibitor (e.g. nilotinib) of about Img or higher, such as about 50mg or higher, such as about lOOmg or higher, preferably about 150mg or higher, or about 200mg or higher, such as about 300mg or higher, or about 400mg or higher, for example about 600mg or higher. The dosage, or dosage form, of the tyrosine kinase inhibitor, may be about 2.0g or lower, such as about 1.5g or lower, preferably about 1.0g (lOOOmg) or lower, such as about 800mg or lower, or about 600mg or lower, or about 500mg or lower, such as about 550mg or lower, for example about 400mg or lower, or about 300mg or lower. The dosage, or dosage form, of the tyrosine kinase inhibitor may be from about Img to about 2.0g, preferably from about lOOmg to about 1.0g, such as from about 200mg to about 600mg. The doses mentioned in this paragraph may be daily doses.More preferably the dose of the tyrosine kinase inhibitor is from about 150 mg to about 600mg, especially from about 300mg to about 600mg, yet more preferably about 400mg. These doses may be daily doses.

[0133] Specific preferred daily doses of the tyrosine kinase inhibitor include about 150mg, about 300mg, about 400mg and about 600mg.

[0134] A dosage, or dosage form, according to the invention may comprise the PLA2 inhibitor (e.g. varespladib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 250mg to about 1250g), and / or the matrix metalloprotease inhibitor (e.g. marimastat) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 200mg to about lOOOmg), and / or the tyrosine kinase inhibitor (e.g. nilotinib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 150mg to about 600mg). A dosage, or dosage form, according to the invention preferably comprises the PLA2 inhibitor (e.g. varespladib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 250mg to about 1250g), and the matrix metalloprotease inhibitor (e.g. marimastat) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 200mg to about lOOOmg), and the tyrosine kinase inhibitor (e.g. nilotinib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 150mg to about 600mg).

[0135] The present invention may relate to additionally administering another therapeutic and / or inhibitor of venom toxins, such as an antivenom. For example, methods and uses of the invention may comprise administering the other therapeutic and / or inhibitor of venom toxins; and kits and compositions of the invention may comprise the therapeutic and / or inhibitor of venom toxins, such as an antivenom. The antivenom may comprise antibodies, such as polyclonal, monoclonal and / or recombinant antibodies, and / or their derivatives (especially fragment antigen-binding (Fab), F(ab’)2 fragment and / or single-domain antibody (sdAb) thereof). Antibodies may include toxin-specific antibodies, humanised recombinant antibody fragments, and / or other related antibody derivatives. Antibodies may include synthetic versions of antibodies and / or recombinant derivatives. Exemplary antivenoms include polyvalent antivenoms produced against multiple venoms (equine or ovine), such as Crotalidae polyvalent immune Fab (ovine).

[0136] Administration regimen

[0137] The compounds and compositions of the invention may be administered to a human or animal subject, for example, a subject that is a mammal, preferably a human. The mammal may be nonhuman. Suitable non-human animals include, but are not limited to, primates (such as marmosetsand monkeys), commercially farmed animals (such as birds, horses, cows, sheep and pigs) and domestic animals (such as dogs, cats, mice, rats, guinea pigs, ferrets, gerbils and hamsters).

[0138] The compounds and compositions of the invention can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration. Preferably the compounds and compositions of the invention of the invention are for oral administration.

[0139] The PLA2 inhibitor, the matrix metalloprotease inhibitor, and the tyrosine kinase inhibitor may be administered simultaneously, sequentially or separately.

[0140] The claimed invention may comprise the administration of a composition comprising the PLA2 inhibitor, the matrix metalloprotease inhibitor, and the tyrosine kinase inhibitor. The claimed invention may comprise the administration of a composition comprising the PLA2 inhibitor and the tyrosine kinase inhibitor; the PLA2 inhibitor and the matrix metalloprotease inhibitor; and / or the matrix metalloprotease inhibitor, and the tyrosine kinase inhibitor. It is preferable for the matrix metalloprotease inhibitor to be administered for the first few days; as such, preferably, the PLA2 inhibitor and the tyrosine kinase inhibitor are administered as a composition, and simultaneously, sequentially or separately to the matrix metalloprotease inhibitor.

[0141] Administration may begin 1 minute or more, such as 2 minutes or more, or 5 minutes or more following envenomation, such as 30 minutes or more, or 2 hours or more, for example 6 hours following envenomation. Administration may begin 2 months or less following envenomation, such as 1 month or less following envenomation, preferably 2 weeks or less following envenomation, or 1 week or less following envenomation, for instance 5 days or less, or 2 days or less following envenomation. Preferably administration begins 1 day or less following envenomation, such as 12 hours or less, or 6 hours or less, more preferably 2 hours or less, such as 30 minutes or less, or 20 minutes or less, such as 15 minutes or less. Administration may begin from 1 minute to 2 months following envenomation, such as from 30 minutes to 2 weeks following envenomation, preferably from 1 minute to 6 hours following envenomation, such as from 5 to 15 minutes following envenomation.

[0142] The tyrosine kinase inhibitor (e.g. nilotinib) may be administered at a frequency of from six times per day to once per week, such as five times per day to once per week, preferably four times per day to once per week, or three times per day to once per week, such as from two times per day to once per week, or from once per day to once per week. The tyrosine kinase inhibitor may be administered at a frequency of from six times per day to once every three days, such asfour times per day to once every three days, such as from four times per day to once every two days, or from four times per day to once daily. The tyrosine kinase inhibitor may be administered at a frequency of three times per day to once every two days, more preferably twice daily (i.e. two times per day). Preferably the tyrosine kinase inhibitor is administered at a frequency of six times per day to once per day, such as four times per day. More preferably the tyrosine kinase inhibitor is administered at an initiation frequency of six times per day to once per day (e.g. four times per day) for the first day or the first two days, and then (following that) at a maintenance frequency of two times per day to once per week (e.g. one time per day).

[0143] The duration of administration of the tyrosine kinase inhibitor (or its combinations) may be 2 days or more, such as 5 days or more, preferably 7 days or more, for example 10 days or more, or 12 days or more, especially 13 or 14 days or more. The duration of administration of the tyrosine kinase inhibitor may be 6 months or less, such as 2 months or less, preferably 1 month or less, such as 21 days or less, or 18 days or less, for example, 15 or 14 days or less. The duration of administration of the tyrosine kinase inhibitor may be from 2 days to 6 months, preferably from 7 days to 1 month, such as from 10 to 21 days. For the tyrosine kinase inhibitor, the administration frequency may be from four times per day to once per week, and the duration of administration may be 2 days or more, such as 7 days or more, for example from 7 days to 1 month. Preferably the duration of administration of the tyrosine kinase inhibitor is 10 days.

[0144] The tyrosine kinase inhibitor may be administered in a dose of about Img or higher (e.g. from about Img to about 2.0g, preferably from about lOOmg to about 1.0g) at a frequency of four times per day to once per week (preferably from three times daily to once every two days, more preferably twice daily), and optionally for a duration of 2 days or more (e.g. 7 days or more, for example from 7 days to 1 month).

[0145] The PLA2 inhibitor may be administered at a frequency of from six times per day to once per week, such as five times per day to once per week, preferably four times per day to once per week, or three times per day to once per week, such as from two times per day to once per week, or from once per day to once per week. The PLA2 inhibitor may be administered at a frequency of from six times per day to once every three days, such as four times per day to once every three days, such as from four times per day to once every two days. Preferably the PLA2 inhibitor is administered at a frequency of three times per day to once every two days, more preferably twice daily. Preferably the PLA2 inhibitor is administered at a frequency of six times per day to once per day, such as four times per day. More preferably the PLA2 inhibitor is administered at an initiation frequency of six times per day to once per day (e.g. four times per day) for the firstday or the first two days, and then (following that) at a maintenance frequency of two times per day to once per week (e.g. one time per day).

[0146] The duration of administration of the PLA2 inhibitor (or its combinations) may be 2 days or more, such as 5 days or more, preferably 7 days or more, for example 10 days or more, or 12 days or more, especially 13 or 14 days or more. The duration of administration of the PLA2 inhibitor may be 6 months or less, such as 2 months or less, preferably 1 month or less, such as 21 days or less, or 18 days or less, for example 15 or 14 days or less. The duration of administration of the PLA2 inhibitor may be from 2 days to 6 months, preferably from 7 days to 1 month, such as from 10 to 21 days. For the PLA2 inhibitor, the administration frequency may be from three times per day to once per week, and the duration of administration may be 2 days or more, such as 7 days or more, for example from 7 days to 1 month. Preferably the duration of administration of the PLA2 inhibitor is 10 days.

[0147] The PLA2 inhibitor may be administered in a dose of about Img or higher (e.g. from about Img to about 2.0g, preferably from about lOOmg to about 1.0g) at a frequency of four times per day to once per week (preferably from three times daily to once every two days, more preferably twice daily), and optionally for a duration of 2 days or more (e.g. 7 days or more, for example from 7 days to 1 month).

[0148] The daily dosage of the PLA2 inhibitor (e.g. varespladib) may be about 50mg or higher, such as about lOOmg or higher, or about 200mg or higher. Preferably the daily dosage of the PLA2 inhibitor is about 250mg or higher, such as about 500mg or higher, or about lOOOmg or higher. The daily dosage of the PLA2 inhibitor may be about 2000mg or lower, such as about 1500mg or lower. Preferably the daily dosage of the PLA2 inhibitor is about 1250mg or lower, such as about lOOOmg or lower, or about 500mg or lower. The daily dosage of the PLA2 inhibitor may be from about 50mg to about 2000mg, preferably from about 250mg to about 1250g, especially about 500mg to about 1250g, more preferably about lOOOmg. Specific preferred daily doses of the PLA2 inhibitor include about 250mg, about 500mg, about lOOOmg and about 1250mg.

[0149] The daily dosage of the matrix metalloprotease inhibitor (e.g. marimastat) may be about 50mg or higher, such as about lOOmg or higher, or about 150mg or higher. Preferably the daily dosage of the matrix metalloprotease inhibitor is about 200mg or higher, such as about 400mg or higher, or about 800mg or higher. The daily dosage of the matrix metalloprotease inhibitor may be about 2000mg or lower, such as about 1500mg or lower, or about 1250mg or lower. Preferably the daily dosage of the matrix metalloprotease inhibitor is about lOOOmg or lower, such as about 800mg or lower, or about 400mg or lower. The daily dosage of the matrix metalloproteaseinhibitor may be from about 50mg to about 2000mg, preferably from about 200mg to about lOOOmg, especially from about 400mg to about lOOOmg, more preferably about 800mg. Specific preferred daily doses of the matrix metalloprotease inhibitor include about 200mg, about 400mg, about 800mg and about lOOOmg. Preferably the duration of administration of the matrix metalloprotease inhibitor is 10 days or fewer; more preferably 3 days.

[0150] The daily dosage of the tyrosine kinase inhibitor (e.g. nilotinib) may be about 50mg or higher, such as about lOOmg or higher. Preferably the daily dosage of the tyrosine kinase inhibitor is about 150mg or higher, such as about 300mg or higher, or about 400mg or higher. The daily dosage of the tyrosine kinase inhibitor may be about 2000mg or lower, such as about 1500mg or lower, or about lOOOmg or lower, such as about 800mg or lower. Preferably the daily dosage of the tyrosine kinase inhibitor is about 600mg or lower, such as about 400mg or lower, or about 300mg or lower. The daily dosage of the tyrosine kinase inhibitor may be from about 50mg to about 2000mg, preferably from about 150mg to about 600mg, especially from about 300mg to about 600mg, more preferably about 400mg.

[0151] An administration regimen may comprise administering the PLA2 inhibitor (e.g. varespladib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 250mg to about 1250g), and / or administering the matrix metalloprotease inhibitor (e.g. marimastat) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 200mg to about lOOOmg), and / or administering the tyrosine kinase inhibitor (e.g. nilotinib) at a daily dose of about 50mg or higher (e.g. from about 50mg to about 2000mg, preferably from about 150mg to about 600mg). Preferably the administration regimen comprises administering the tyrosine kinase inhibitor and at least one of the PLA2 inhibitor and the matrix metalloprotease inhibitor; more preferably the administration regimen comprises administering the tyrosine kinase inhibitor, the PLA2 inhibitor and the matrix metalloprotease inhibitor.

[0152] According to one administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently), and the daily dose of the tyrosine kinase inhibitor is about 150mg, the daily dose of the matrix metalloprotease inhibitor is about 200mg, and the daily dose of the PLA2 inhibitor is about 250mg.

[0153] According to another administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently), and the daily dose of the tyrosine kinase inhibitor is about 300mg, the daily dose of the matrixmetalloprotease inhibitor is about 400mg, and the daily dose of the PLA2 inhibitor is about 500mg.

[0154] According to a preferable administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently), and the daily dose of the tyrosine kinase inhibitor is about 400mg, the daily dose of the matrix metalloprotease inhibitor is about 800mg, and the daily dose of the PLA2 inhibitor is about lOOOmg.

[0155] According to another administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently), and the daily dose of the tyrosine kinase inhibitor is about 600mg, the daily dose of the matrix metalloprotease inhibitor is about lOOOmg, and the daily dose of the PLA2 inhibitor is about 1250mg.

[0156] Compounds may be administered as an initial “loading” dose and a subsequent “maintenance” dose. Typically the loading dose is higher than the maintenance dose. This is defined more specifically in the following paragraphs.

[0157] According to another administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 1, 2 and 3, and the tyrosine kinase inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 4-7. The daily dose of the tyrosine kinase inhibitor on day 1 is about 300mg, the daily dose of the matrix metalloprotease inhibitor on day 1 is about 400mg, and the daily dose of the PLA2 inhibitor on day 1 is about 500mg. The daily dose of the tyrosine kinase inhibitor on each of days 2 and 3 is about 150mg, the daily dose of the matrix metalloprotease inhibitor on each of days 2 and 3 is about 200mg, and the daily dose of the PLA2 inhibitor on each of days 2 and 3 is about 250mg. The daily dose of the tyrosine kinase inhibitor on each of days 4 to 7 is about 150mg, and the daily dose of the PLA2 inhibitor on each of days 4 to 7 is about 250mg. The daily doses administered on day 7 may be repeated daily until day 10.

[0158] According to another preferable administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 1, 2 and 3, and the tyrosine kinase inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 4-7. The daily dose of the tyrosine kinase inhibitor on day 1 is about 400mg, the daily dose of the matrix metalloprotease inhibitor on day 1 is about 800mg, and the daily dose of the PLA2 inhibitor on day 1 is about lOOOmg. The daily dose of the tyrosine kinaseinhibitor on each of days 2 and 3 is about 300mg, the daily dose of the matrix metalloprotease inhibitor on each of days 2 and 3 is about 400mg, and the daily dose of the PLA2 inhibitor on each of days 2 and 3 is about 500mg. The daily dose of the tyrosine kinase inhibitor on each of days 4 to 7 is about 300mg, and the daily dose of the PLA2 inhibitor on each of days 4 to 7 is about 500mg. The daily doses administered on day 7 may be repeated daily until day 10.

[0159] According to another administration protocol, the tyrosine kinase inhibitor, the matrix metalloprotease inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 1, 2 and 3, and the tyrosine kinase inhibitor and the PLA2 inhibitor are administered (e.g. concurrently) on days 4-7. The daily dose of the tyrosine kinase inhibitor on day 1 is about 600mg, the daily dose of the matrix metalloprotease inhibitor on day 1 is about lOOOmg, and the daily dose of the PLA2 inhibitor on day 1 is about 1250mg. The daily dose of the tyrosine kinase inhibitor on each of days 2 and 3 is about 400mg, the daily dose of the matrix metalloprotease inhibitor on each of days 2 and 3 is about 800mg, and the daily dose of the PLA2 inhibitor on each of days 2 and 3 is about lOOOmg. The daily dose of the tyrosine kinase inhibitor on each of days 4 to 7 is about 400mg, and the daily dose of the PLA2 inhibitor on each of days 4 to 7 is about lOOOmg. The daily doses administered on day 7 may be repeated daily until day 10.

[0160] The matrix metalloprotease inhibitor may be administered as a one-off or multiple doses. The matrix metalloprotease inhibitor may be administered at a frequency of from six times per day to once per week, such as five times per day to once per week, preferably four times per day to once per week, or three times per day to once per week, such as from two times per day to once per week, or from once per day to once per week. The matrix metalloprotease inhibitor may be administered at a frequency of from six times per day to once every three days, such as four times per day to once every three days, such as from four times per day to once every two days. Preferably the matrix metalloprotease inhibitor is administered at a frequency of three times per day to once every two days, more preferably twice daily. Preferably the matrix metalloprotease inhibitor is administered at a frequency of six times per day to once per day, such as four times per day. More preferably the matrix metalloprotease inhibitor is administered at an initiation frequency of six times per day to once per day (e.g. four times per day) for the first day or the first two days, and then (following that) at a maintenance frequency of two times per day to once per week (e.g. one time per day).

[0161] The duration of administration of the matrix metalloprotease inhibitor (or its combinations) may be 1 day or more, preferably 2 days or more, or 3 days or more. The duration of administration of the matrix metalloprotease inhibitor may be 1 month or less, preferably 14 days or less, such as 10 days or less, more preferably 7 days or less, such as 5 days or less, or 4 days or less, forexample 3 days or less. The duration of administration of the matrix metalloprotease inhibitor may be from 1 days to 1 month, preferably from 2 days to 7 days, such as from 2 to 5 days. For the matrix metalloprotease inhibitor, the administration frequency may be from three times per day to once per week (e.g. from three times per day to once every three days), and the duration of administration may be 1 day or more, such as from 1 day to 1 month, preferably from 2 days to 7 days.

[0162] The matrix metalloprotease inhibitor may be administered in a dose of about Img or higher (e.g. from about Img to about 2.0g, preferably from about lOOmg to about 1.0g) at a frequency of four times per day to once per week (preferably from three times daily to once every two days, more preferably twice daily), and optionally for a duration of 1 day or more (e.g. from 1 day to 1 month, preferably from 2 days to 7 days, more preferably 3 days).

[0163] The method may comprise administering the tyrosine kinase inhibitor at a frequency of from three times per day to once per week (e.g. twice daily to once every two days), administering the PLA2 inhibitor at a frequency of from three times per day to once per week (e.g. twice daily to once every two days), and administering the matrix metalloprotease inhibitor as a one-off dose or at a frequency of from three times per day to once per week (e.g. twice daily to once every two days).

[0164] The method may comprise: administering the tyrosine kinase inhibitor at a frequency of from three times per day to once per week, and for a duration of 2 days or more (for example from 7 days to 1 month); and administering the PLA2 inhibitor at a frequency of from three times per day to once per week, and for a duration of 2 days or more (for example from 7 days to 1 month); and administering the matrix metalloprotease inhibitor as a single dose, or administering the matrix metalloprotease inhibitor at a frequency of from three times per day to once per week (e.g. from three times per day to once every three days) and for a duration of 1 day or more (preferably from 2 days to 7 days).

[0165] It will be appreciated that the daily doses mentioned herein may be achieved using one or more doses of the composition, or its component medicaments, for example as separate formulations (e.g. tablets and / or capsules) administered throughout the day.

[0166] Treatment Outcomes

[0167] Treatment in accordance with the invention may improve survival rate after 48 hours compared to control (e.g. no treatment). The survival rate after 48 hours may be increased by 10% or morecompared to control, such as 20% or more, or 50% or more, such as 100% or more compared to control.

[0168] Treatment in accordance with the invention may reduce haemorrhaging after 48 hours compared to control (e.g. no treatment). The haemorrhage rate after 48 hours may be reduced by 10% or more compared to control, such as 20% or more, or 50% or more, such as 100% or more compared to control. Haemorrhage rate may be determined by prothrombin time (PT) test and / or activated partial thromboplastin time (aPTT) test, and optionally calculating an INR (international normalized ratio). Haemorrhage rate may be determined by visual inspection, or by measurement of biomarkers such as blood biomarkers. Such biomarkers may include prothrombin and / or activated partial thromboplastin.

[0169] Examples

[0170] The data shown in Figures 1-6 represent mean ± S.D. Statistical significance was assessed using one-way ANOVA in Figures 1, 2, 4, 5 and 6. For Figure 3, a Student's t-test was employed. The p values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. # and & denote the same p-value thresholds.

[0171] Example 1: Russell’s viper venom damages the cultured myoblasts and myotubes Russell’s viper venom caused significant damage to cultured human myoblast (AB 1190) and embryonic kidney (HEK293T) cell lines at concentrations of 6.25 pg / mL and above. In line with these data, Russell’s viper venom substantially affected the area of cultured myotubes and compromised the differentiation capacity of human (AB1167 GFP-expressing) myoblasts.

[0172] Biochemical characterisation revealed that Russell’s viper venom has high metalloprotease activity. SDS-PAGE and reverse-phase high-performance liquid chromatography analyses confirmed the protein profile for venom with a prominent protein at ~65kDa, which was confirmed as a PHI metalloprotease by mass spectrometry analysis.

[0173] Notably, the currently used polyvalent antivenom (comprising antibodies produced against venom proteins in hyperimmunised animals such as horses) produced against the Indian ‘Big Four’ snakes (Russell’s viper, cobra, krait and saw-scaled viper) failed to prevent the venom-induced damage in human myoblasts and embryonic kidney cells although it partially reversed the damage. These data demonstrate that the venom contains higher levels of metalloproteases, which are likely to cause extensive muscle damage.Example 2: Varespladib and marimastat only partially reverse venom-induced muscle damage in mice (comparative)

[0174] To determine the effect of Russell’s viper venom (DR) in inducing muscle damage and the ability of varespladib (V) and marimastat (M) to prevent such damage, an in vivo experiment in mice was performed. Animals were divided into different groups (6 in each), and they received drugs or antivenom (AV) alone or different combinations of these therapeutics. The venom (10 pg) was administered intramuscularly (i.m.) into the TA muscle of mice. Then varespladib (120 pg) and marimastat (120 pg) were administered intraperitoneally (i.p.) after a one-hour injection of venom, and then they [varespladib (60 pg) and marimastat (60 pg)] were injected at every 24 hours until the muscle was collected at days 1, 3, 7 and 14. NC=ncgativc control. The percentage of muscle loss following venom injection with / without drugs on day 14 was calculated by comparing the venom-damaged TA muscle with the control TA muscles (considered as 100%). These data demonstrate that varespladib and its combination with AV showed some protection from muscle loss, although muscle loss was not completely averted.

[0175] Figure 1 of the accompanying drawings shows the results of this study. * represents the comparison of all bars with DR (Russell’s viper venom alone) and # represents the comparison with the negative control.

[0176] The venom administration resulted in -20% muscle weight loss by day 14. However, the administration of varespladib largely prevented this muscle loss, although marimastat did not display a significant effect.

[0177] Haematoxylin and eosin (H&E)-stained sections revealed that on day 1, the venom-induced excessive necrosis of muscle fibres, oedema and immune response, which are more evident on day 3. By day 7, venom-treated muscles showed early signs of muscle regeneration (as evidenced through centrally located nuclei) yet with significant necrotic areas. Incomplete regeneration, atrophic muscle fibres and fibrous tissues are evident on day 14. In line with these data, venom increased IgG infiltration and reduced the levels of dystrophin, laminin and collagen IV at different time points. The presence of embryonic myosin heavy chain (eMHC) at the later stages indicates ongoing damage. The angiogenesis was also affected in venom-treated muscle in the early stages, as evidenced by reduced expression of CD31. These data demonstrate that Russell’s viper venom induces extensive damage to the ECM, blood capillaries and muscle fibres via necrosis.

[0178] Varespladib and its combination with marimastat reduced the level of muscle damage and promoted regeneration by day 14. However, marimastat alone did not promote muscleregeneration to the same extent as varespladib or its combination with varespladib or antivenom. Notably, varespladib and its combination with antivenom slightly increased the muscle fibre size, but marimastat did not exert this effect. Varespladib and its combinations retained the architecture of laminin, but marimastat did not prevent damage to laminin. Moreover, varespladib reduced the IgG infiltration and increased the dystrophin and eMHC levels at different time points. Antivenom alone, or its combination with marimastat, did not offer significant benefits to the damaged muscle. These data suggest that varespladib and its combinations are capable of preventing venom-induced muscle damage to an extent. The antivenom alone did not offer any benefits in preventing venom-induced muscle damage.

[0179] The drugs or antivenom alone did not cause any adverse damage to the muscles or systemically in the animals.

[0180] Example 3: Venom-induced fibrosis is not fully prevented by varespladib and marimastat (comparative)

[0181] Figure 2 of the accompanying drawings shows the impact of drugs and antivenom in controlling fibrosis following venom-induced damage, specifically showing the collagen contents in venom (with / without drugs and antivenom)-treated mice, by picrosirius red positive area, ^represents the comparison of all bars with DR; # represents comparison with the negative control; and & represents the comparison between varespladib and marimastat alone following venom-induced damage.

[0182] Russell’s viper venom-induced an excessive development of fibrosis in the damaged muscle. While varespladib reduced the fibrosis slightly more than marimastat, it was unable to fully prevent this condition. Marimastat and antivenom, as well as their combinations, displayed only a limited benefit in reducing fibrosis. The drugs and antivenom alone did not cause any alterations to the ECM or induce fibrosis.

[0183] The results obtained from marimastat-treated mice are surprising as it was expected that the inhibition of venom metalloproteases would prevent damage to the ECM and promote muscle regeneration without fibrosis. Based on these data, it was hypothesised that the long-term administration of marimastat affects the activity of newly expressed matrix metalloproteases that are critical for the remodelling of the ECM, which in turn promotes muscle regeneration.

[0184] To establish if marimastat disrupts muscle regeneration and promotes fibrosis in the absence of venom metalloproteases, marimastat was tested in a cardiotoxin (CTX, a non-enzymatic 3FTX, similar to notexin mentioned above) -induced muscle damage model in mice. Tissue sampleswere analysed to determine the TA muscle weight loss, the picrosirius red positive area, and the percentage collagen deposition.

[0185] The results of this study are shown by Figure 3A-C of the accompanying drawings.

[0186] As expected, CTX-damaged muscle had fully regenerated by day 14 without any significant weight loss (Figure 3A). The regenerated fibres with centrally located nuclei are evident throughout the CTX-damaged muscle. However, CTX+marimastat-treated mice showed significant muscle weight loss and poor regeneration, as demonstrated through smaller regenerating fibres and significant infiltration of leukocytes. The percentage TA muscle weight loss, picrosirius red positive area and percentage collagen deposition were all increased in tissues of subjects treated with CTX and marimastat, compared to CTX alone (Figures 3A-C). Notably, the fibrotic area was not observed in CTX-treated muscles, although marimastat treatment resulted in a higher amount of fibrosis and laminin (data not shown in Figures). There were no differences observed in the expression of CD31 and dystrophin and IgG levels (data not shown in Figures).

[0187] Overall, these data confirm that the long-term use of marimastat can detrimentally affect muscle regeneration, leading to smaller fibres and fibrosis.

[0188] Example 4: Treatment with varespladib, marimastat and nilotinib tackles fibrosis and promotes perfect muscle regeneration following venom-induced damage (invention)

[0189] The ability of varespladib, marimastat and nilotinib to promote regeneration and control fibrosis in Russell’s viper venom-damaged muscle was analysed.

[0190] Figure 4A-C shows the results of this study into the impact of nilotinib, and combination therapies comprising nilotinib, on the promotion of muscle regeneration and the control of fibrosis.

[0191] The p values (*p<0.1, **p<0.01, ***p<0.001 and ****p<0.0001) shown are as calculated using one-way ANOVA followed by Dunnett’s post-hoc test. Asterisks (*) represent the comparison of all bars with the venom-alone group and hashes (#) denote the comparison of combination therapy with nilotinib alone or nilotinib + varespladib groups.

[0192] As shown by Figure 4A, nilotinib alone did not offer any protective effects in TA muscle in mice that were treated with venom, as there was no muscle weight loss. However, the combination of nilotinib and varespladib, and the combination also including marimastat each significantlyreduced the amount of muscle weight loss, ^represents the comparison of all bars with DR.#represents the comparison of nilotinib alone with the full combination therapy.

[0193] To develop a substantial level of fibrosis to study the impact of nilotinib under in vivo settings, the dose of venom was increased to 17.5 pg / 20 g mouse, which indeed resulted in extensive fibrosis.

[0194] As shown in Figure 4B, the daily administration of nilotinib dramatically reduced venom-induced fibrosis by day 14 compared to the venom-alone group (DR) as determined by picrosirius red staining, ^represents the comparison of all bars with DR.#when comparing nilotinib alone with the full combination therapy.

[0195] Furthermore, a combination of varespladib and nilotinib showed better anti-fibrotic effects. Despite positive outcomes, fibrosis and necrotic areas were still observed in this combination treatment involving varespladib and nilotinib.

[0196] However, a combination of varespladib (daily), nilotinib (daily) and marimastat (only for the first three days after venom administration) completely prevented the fibrosis following venom-induced damage, and the muscle looked very similar to the undamaged control muscles. The remaining picrosirius red positive area shown in combination therapy is the same as in the undamaged muscle, confirming there is no fibrosis.

[0197] Further H&E staining of muscle sections was performed to determine the percentage of damaged tissue area. Figure 4C of the accompanying drawings shows the results of this study. The analysis revealed a large amount of damage with infiltration of leukocytes and very few regenerating fibres in venom-treated muscles. However, the combination of three drugs (including nilotinib) substantially reduced such effects and fully promoted regeneration of the muscle tissue. The combination therapy provides much better results than nilotinib alone or nilotinib with varespladib.

[0198] Figure 5 of the accompanying drawings shows the effects of nilotinib; nilotinib and varespladib; and varespladib, nilotinib and marimastat on laminin (Figure 5A) and dystrophin (Figure 5B) levels in envenomated muscle tissue, compared to venom-alone group, ^represents the comparison of all bars with DR. # represents the comparison of nilotinib alone and nilotinib + varespladib with full combination therapy. Higher levels of laminin and dystrophin were detected in muscles when treated with either nilotinib alone or the combinations. Levels of dystrophin were particularly enhanced by the combination of nilotinib and varespladib, and particularlysignificant increases in the levels of dystrophin were observed following treatment with the combination of varespladib, nilotinib and marimastat.

[0199] Figure 6 of the accompanying drawings shows the effects of nilotinib; nilotinib and varespladib; and varespladib, nilotinib and marimastat on markers of cellular and tissue repair, compared to venom-alone group, ^represents the comparison of all bars with DR.

[0200] Specifically, the level of immunoglobulin G (IgG) infiltration was substantially decreased by nilotinib alone; the combination of nilotinib with varespladib provided a further decrease; and a complete decrease was attained with the combinational therapy also including marimastat (Figure 6A).

[0201] Furthermore, the level of cluster of differentiation 31 (CD31, also known as platelet endothelial cell adhesion molecule 1) was also reduced by each of nilotinib alone, the combination of nilotinib with varespladib, and the combinational therapy also including marimastat (Figure 6B).

[0202] In addition, the level of fibro / adipogenic progenitor (FAP) marker, platelet-derived growth factor receptor a (PDGFRa) was significantly reduced by each of nilotinib alone, the combination of nilotinib with varespladib, and the combinational therapy also including marimastat (Figure 6C).

[0203] These data suggest that a treatment regimen comprising nilotinib can significantly prevent and treat Russell’s viper venom-induced muscle damage and fibrosis. Further enhanced effects have been observed in relation to the combination of nilotinib and varespladib; and yet further enhanced effects were observed for the combination of varespladib, nilotinib and marimastat. Surprisingly, following the administration of the combination therapy including varespladib, nilotinib and marimastat, fibrosis was completely reversed and muscle tissue appeared completely healthy.

[0204] Single Dose Lethality Assay

[0205] The venom of a snake was injected into 5 to 12 mice by intraperitoneal administration. The amount of venom was calculated based on the published LD50 value for the venom. After five minutes, a single dose of 125 pg varespladib, 125 pg marimastat, and 200 pg nilotinib, dissolved in DMSO, was injected intraperitoneally into each mouse. The mice were monitored for their survival for up to 48 hours. Control mice were not treated (only vehicle control was used) following envenomation.The procedure was repeated with venoms of the following snakes: Bungariis caeruleiis (Common krait), Naja naja (Indian cobra), Echis carinatus (Saw-scaled viper), Daboia russelii (Russell's viper), Bitis arietans (Puff adder), Crotalus atrox (Western diamondback rattlesnake), Bothrops atrox (Common lancehead), Vipera berus (European adder), Micruriis obscuriis (Coral snake), Oxyranus scutellatus (Coastal taipan), Dendroaspis polylepis (Black mamba), Acanthopis riigosus (Death adder), Agkistrodon laticinctus (Broad-banded copperhead), Agkistrodon contortrix (Copperhead), Agkistrodon bilineatus (Cantil viper), Agkistrodon piscivorus (Cottonmouth), Agkistrodon taylori (Taylor's cantil), Atractaspis fallax (Peters' burrowing asp), Agkistrodon leucostoma (Western cottonmouth), Bitis rhinoceros (Gaboon viper), Bitis nasicornis (Butterfly viper), Bothrops alternatus (Crossed pit viper), Bothrops atrox from Suriname (Lancehead), Bothrops atrox from Columbia (Lancehead), Bothrops asper (Fer-de- lance), Bothrops atrox from Guyana (Lancehead), Bungariis Candidas (Malayan krait), Bungarus fasciatus (Banded cobra), Bothrops moojeni (Brazilian lancehead), Bothrops jararacussu (Jararacussu), Calloselasma rhodostoma (Malayan pit viper), Crotalus scutulatus scutulatus from Arizona (Mohave rattlesnake), Craspedocephalus puniceus (Flat-nosed pit viper), Crotalus horridus (Timber rattlesnake), Crotalus scutulatus scutulatus from Texas (Mohave rattlesnake), Crotalus viridis viridis (Prairie rattlesnake), Deinagkistrodon acutus (Chinese moccasin), Echis leucogaster (White-bellied carpet viper), Echis pyramidum (Northeast African carpet viper), Dendroaspis viridis (Western green mamba), Echis ocellatus (West African carpet viper), Hypnale hypnale (Hump-nosed pit viper), Lachesis muta (Bushmaster), Macrovipera lebetinus tauranica (Lebetine viper), Echis sochureki (Sochurek's saw-scaled viper), Naja guineensis (Black forest cobra), Naja annulata (Banded water cobra), Montivipera xanthina (Rock viper), Metlapilcoatlus mexicanum (Central American jumping pit viper), Naja nigricollis (Blacknecked spitting cobra), Naja haje (Egyptian cobra), Naja nana (Dwarf water viper), Naja nivea (Cape viper), Naja savannula (West African banded cobra), Naja subfulva (Brown forest cobra), Naja pallida (Red spitting cobra), Ovophis okinavensis (Hime habu), Oxyuranus scutellatus scutellatus (Coastal taipan), Oxyuranus microlepidotus (Inland taipan), Oxyuranus scutellatus canni (Coastal taipan), Protobothrops elegans (Elegant pit viper), Trimeresurus insularis (Indonesian pit viper), Pseudechis colletti (Collett's black snake), Macrovipera mauritanica (Moorish viper), Vipera ammodytes (Horned viper), Trimeresurus purpureomaculatus (Mongrove pit viper), Naja annulifera (Snouted cobra), and Naja mossambica (Mozambique spitting cobra).

[0206] The results are shown in Figures 7 to 77 of the accompanying drawings.For Bungarus caeruleus (Common krait), Naja naja (Indian cobra), Echis carinatus (Saw-scaled viper), and Daboia russelii (Russell's viper), as a comparison, other mice were treated with antivenom, and their survival was monitored, in accordance with the method described above.

[0207] In all cases except for Trimeresuriis purpiireomaciilatiis (Mongrove pit viper), the venom alone (control) 100% mortality was observed in less than 48 hours, and in many cases 100% mortality was observed in less than 6 hours. For Trimeresuriis purpureomaculatus (Mongrove pit viper), the venom achieved 83% mortality within about an hour.

[0208] In all cases, the combination of compounds of the invention provided higher rates survival than control (no treatment following envenomation).

[0209] When the combination of compounds of the invention was used to treat envenomation by the following venoms, the survival rate was 25% or higher after 48 hours: Naja naja, Echis carinatus, Daboia russelii, Bitis arietans, Crotalus atrox, Bothrops atrox, Vipera berus, Oxyranus scutellatus, Agkistrodon laticinctus, Agkistrodon contortrix, Agkistrodon bilineatus, Agkistrodon piscivorus, Agkistrodon taylori, Atractaspis fallax, Agkistrodon leucostoma, Bitis rhinoceros, Bitis nasicornis, Bitis arietans, Bothrops atrox from Columbia, Bothrops asper, Bothrops atrox from Guyana, Bungarus fasciatus, Bothrops jararacussu, Calloselasma rhodostoma, Crotalus scutulatus scutulatus from Arizona, Crotalus horridus, Crotalus scutulatus scutulatus from Texas, Crotalus viridis viridis, Echis pyramidum, Hypnale hypnale, Lachesis muta, Macrovipera lebetinus tauranica, Naja guineensis, Montivipera xanthina, Naja nigricollis, Naja haje, Naja savannula, Naja pallida, Ovophis okinavensis, Oxyuranus scutellatus scutellatus, Oxyuranus microlepidotus, Oxyuranus scutellatus canni, Protobothrops elegans, Pseudechis colletti, Vipera ammodytes, Trimeresurus purpureomaculatus , and Naja mossambica.

[0210] When the combination of compounds of the invention was used to treat envenomation by the following venoms, the survival rate was 50% or higher after 48 hours: Daboia russelii, Bitis arietans, Crotalus atrox, Bothrops atrox, Vipera berus, Oxyranus scutellatus, Agkistrodon laticinctus, Agkistrodon bilineatus, Agkistrodon piscivorus, Agkistrodon taylori, Atractaspis fallax, Agkistrodon leucostoma, Bitis rhinoceros, Bitis nasicornis, Bothrops atrox from Columbia, Bungarus fasciatus, Calloselasma rhodostoma, Crotalus scutulatus scutulatus A, Crotalus horridus, Crotalus scutulatus scutulatus T, Lachesis muta, Ovophis okinavensis, Oxyuranus scutellatus scutellatus, Oxyuranus microlepidotus, Oxyuranus scutellatus canni, Protobothrops elegans, Pseudechis colletti, Vipera ammodytes, Trimeresurus purpureomaculatus , and Naja mossambica.When the combination of compounds of the invention was used to treat envenomation by the following venoms, total (100%) survival after 48 hours was achieved: Bitis arietans, Vipera berus, Agkistrodon laticinctus, Agkistrodon bilineatus, Agkistrodon taylori, Agkistrodon leucostoma, Bitis nasicornis, Bitis arietans, Bothrops atrox from Columbia, Crotalus horridus, Lachesis muta, Oxyuranus scutellatus scutellatus, and Vipera ammodytes.

[0211] This shows that treatment of envenomation with the combination of compounds of the invention can provide significant improvements to the chance of survival of the subject compared to no treatment. Further benefits may also be attained in relation to the reduction of disabling injuries of subjects when envenomation is treated with the combination of compounds of the invention.

[0212] In this study, it was also observed that the muscle damage induced by the venoms of Echis ocellatus, Bothrops atrox, Crotalus atrox and Bitis arietans was significantly mitigated by the combination of compounds of the invention.

[0213] When the combination of compounds of the invention was used to treat envenomation by Daboia russelii (Russell’s viper) venom and compared against treatment by antivenom, survival at any time after 4 hours was higher in the group treated with the combination of compounds of the invention than in the group treated by antivenom. After 48 hours, the survival rates were 60% for the group treated by the invention and 25% for the group treated with antivenom.

[0214] This shows that the combination of compounds of the invention can provide higher survival rates than antivenom.

[0215] When the combination of compounds of the invention was used to treat envenomation by Echis carinatus (Saw-scaled viper) venom and compared against treatment by antivenom, after 6-12 hours, 100% survival was achieved for the combination of compounds of the invention, whereas antivenom achieved 80% survival. However, after 48 hours, survival was higher in the group treated with antivenom (80%) than in the group treated with the combination of compounds of the invention (42%). Furthermore, when the combination of compounds of the invention was used to treat envenomation by venom of Bungarus caeruleus (Common krait) or Naja naja (Indian cobra), 100% survival was maintained for over 4 hours. This is significantly longer than 100% survival was maintained in the control (no treatment) group.

[0216] The combination of compounds of the invention is significantly more stable and easier to transport than antivenom. As such, these data show that the combination of compounds of theinvention provides significant benefits even when it is less effective in the long term than antivenom. For example, rapid treatment of a subject that has been bitten by a snake with the combination of compounds of the invention may increase the chance that the subject remains alive, or in a better condition, before they can be administered antivenom. This may help to improve the long-term prognosis of the subject.

[0217] Multiple Dose Lethality Assay

[0218] Figure 7 shows the results of administering mice venom of snakes of the species Bungariis caeruleiis according to the above-described single dose protocol. The control sample provided 0% survival after about 4 hours. It was seen that the combination of compounds of the invention increased survival rate compared to control significantly over the course of the study, maintaining 100% survival for around 6 hours, before the survival rate decreased to about 30% after 12 hours and about 20% from around 20 hours onwards.

[0219] The effects of administering multiple doses of the combination of compounds of the invention in the first few hours following envenomation were investigated. The protocol described in relation to the single dose study (above) was followed except that, in addition to the initial dose of the combination of compounds of the invention at five minutes after envenomation, further doses of the combination of compounds of the invention were administered at either 6 hours after envenomation (2-dose protocol); or at 4, 8 and 12 hours after envenomation (4-dose protocol).

[0220] The results are shown by Figures 78 (2-dose protocol) and 79 (4-dose protocol) of the accompanying drawings.

[0221] When the combination of compounds of the invention were administered under the 2-dose protocol, survival at 12 hours increased from 30% (under the single dose protocol) to 50%. However, survival remained low after this.

[0222] When the combination of compounds of the invention were administered under the 4-dose protocol, survival at 12 hours increased again to about 65%, and increased to about 35% at the end of the study (48 hours).

[0223] Therefore, multiple doses of the combination of compounds of the invention can provide significant benefits to the survival of subjects after envenomation.Haemorrhagic assay

[0224] The venom of a snake was injected into mice subcutaneously. The amount of venom was calculated based on the published LD50 value for the venom. After five minutes, a single dose including 125 pg varespladib, 125 pg marimastat and 200 pg nilotinib, dissolved in DMSO, was injected intraperitoneally in each mouse. The mice were monitored for their survival and euthanised at 4 or 8 hours after envenomation. The skin of each mouse was opened, and the level of haemorrhagic lesions was measured. Control mice were administered the venom but not the combination of varespladib, marimastat and nilotinib.

[0225] The procedure was repeated with venoms of the following snakes: Bitis arietans (Puff adder), Bothrops atrox (Lancehead viper), Daboia russelii (Russell’s viper), and Echis ocellatus (Carpet viper). Mice treated with venom of Carpet viper were euthanised at 4 hours after envenomation. Mice treated with venom of Puff adder, Lancehead viper, or Russell’s viper were euthanised at 8 hours after envenomation.

[0226] The results are shown by Figure 80 of the accompanying drawings (specifically, Figures 78A and 78B of the accompanying drawings).

[0227] In each case, control mice demonstrated significantly more haemorrhage than mice treated with the combination of compounds of the invention.

[0228] This shows that the combination of compounds of the invention prevents venom-induced excessive bleeding.

[0229] In another experiment, Echis ocellatus (Carpet viper) venom was injected into mice subcutaneously. The amount of venom was calculated based on the published LD50 value for the venom. After five minutes, a single dose including 125 pg varespladib, 125 pg marimastat and 200 pg of either ibrutinib, imatinib or nilotinib, dissolved in DMSO was injected intraperitoneally into each mouse. The mice were monitored for their survival and euthanised at 4 or 8 hours after envenomation. The skin of each mouse was opened, and the level of haemorrhagic lesions was measured. Control mice were administered the venom but not the combination of varespladib, marimastat and either ibrutinib, imatinib or nilotinib.

[0230] The results are shown by Figure 81 of the accompanying drawings.

[0231] Significant amounts of haemorrhage were observed in the skin of the control mice. Haemorrhage was reduced compared to control in the group treated with the combinations of compoundsincluding varespladib, marimastat and either ibrutinib or imatinib. The reduction in haemorrhaging was greater for the combination including imatinib than for the combination including ibrutinib. Almost no haemorrhaging was observed for the group treated with the combination of varespladib, marimastat and nilotinib.

[0232] Nilotinib and imatinib are both types of Bcr-Abl tyrosine-kinase inhibitors, which may rationalise why these two inhibitors are more effective than ibrutinib. Nilotinib is a second generation Bcr-Abl tyrosine-kinase inhibitor, whereas imatinib is a first generation Bcr-Abl tyrosine-kinase inhibitor. This may rationalise why nilotinib is more effective than imatinib.

[0233] This shows that the combination of a tyrosine kinase inhibitor (e.g. ibrutinib, imatinib or nilotinib), with PLA2 inhibitor (e.g. varespladib) and a matrix metalloprotease inhibitor (e.g. marimastat) provides significant benefits compared to control.

[0234] In addition, this shows that further surprising benefits can be attained where the combination includes nilotinib as the tyrosine kinase inhibitor.

Claims

CLAIMS1. A tyrosine kinase inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject.

2. The tyrosine kinase inhibitor for use of claim 1, wherein the tyrosine kinase inhibitor is selected from the list consisting of Acalabrutinib, Adavosertib, Afatinib, Alectinib, Anlotinib, Apatinib, Asciminib, Aumolertinib, Avapritinib, Axitinib, Bafetinib, Bosutinib, Cabozantinib, Canertinib, cetuximab, Crenolanib, Dacomitinib, Damnacanthal, Dasatinib, Entospletinib, Entrectinib, Erlotinib, Foretinib, Fostamatinib, Fruquintinib, Futibatinib, Gefitinib, Gilteritinib, Glesatinib, HS-10365, Ibrutinib, Icotinib, Idelalisib, IDRX-42, Imatinib, Infigratinib, Ivosidenib, Lapatinib, Larotrectinib, Lazertinib, Lenvatinib, Linifanib, Lorlatinib, Masitinib, Midostaurin, Mirdametinib, Mobocertinib, Motesanib, Mubritinib, Nemtabrutinib, Nilotinib, Neratinib, Netarsudil, Nimotuzumab, Nintedanib, Olverembatinib, panitumumab, Pazopanib, Pirtobrutinib, Ponatinib, Radotinib, Regorafenib, Remibrutinib, Repotrectinib, Ropsacitinib, Savolitinib, Selpercatinib, Sorafenib, Sitravatinib, Sunitinib, Sunvozertinib, Tesevatinib, Tolebrutinib, Vatalanib, vandetanib and Zasocitinib.

3. The tyrosine kinase inhibitor for use of claim 2, wherein the tyrosine kinase inhibitor is selected from the list consisting of Asciminib, Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib and Bafetinib.

4. The tyrosine kinase inhibitor for use of claim 3, wherein the tyrosine kinase inhibitor is nilotinib.

5. The tyrosine kinase inhibitor for use of any preceding claim, wherein the method further comprises administering a phospholipase A2 (PLA2) inhibitor.

6. The tyrosine kinase inhibitor for use of claim 5, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, darapladib, manoalide, U-73122, Quinacrine, Quercetin, Chlorpromazine, Aristolochic Acid, Cinnamycin, MJ33, ETYA, N-(p-Amylcinnamoyl) anthranilic acid, ML349 and arachidonyl trifluoromethyl ketone.

7. The tyrosine kinase inhibitor for use of claim 6, wherein the PLA2 inhibitor is selected from the list consisting of varespladib, methyl varespladib, and darapladib.

8. The tyrosine kinase inhibitor for use of claim 7, wherein the PLA2 inhibitor is varespladib.

9. The tyrosine kinase inhibitor for use of any preceding claim, wherein the method further comprises administering a matrix metalloprotease inhibitor.

10. The tyrosine kinase inhibitor for use of claim 9, wherein the matrix metalloprotease inhibitor is selected from the list consisting of marimastat, batimastat (BB-94), prinomastat (AG3340), tanomastat (BAY 12-9566), CGS-27023 (CAS 169799-04-6), ilomastat, doxycycline hyclate, TAPI-1 (CAS 163847-77-6), actinonin, NNGH (CAS 161314-17-6), tissue inhibitors of metalloproteinases, squalamine, genistein, nobiletin, myricetin, curcumin, xanthorhizzol, theaflavin, resveratrol, actinonin, matlystatin B, nicotinamide, betulinic acid, glycyrrhetinic acid, catechin, bryostatins, and tetracyclines.

11. The tyrosine kinase inhibitor for use of claim 10, wherein the matrix metalloprotease inhibitor is marimastat or prinomastat.

12. The tyrosine kinase inhibitor for use of claim 11, wherein the matrix metalloprotease inhibitor is marimastat.

13. The tyrosine kinase inhibitor for use of any one of claims 9 to 12, wherein the matrix metalloprotease inhibitor is administered for a duration of from 2 days to 7 days.

14. The tyrosine kinase inhibitor for use of any one of claims 1 to 4, wherein the method further comprises administering a PLA2 inhibitor and administering a matrix metalloprotease inhibitor.

15. The tyrosine kinase inhibitor for use of claim 14, wherein the tyrosine kinase inhibitor is nilotinib, the matrix metalloprotease inhibitor is marimastat, and the PLA2 inhibitor is varespladib.

16. The tyrosine kinase inhibitor for use of any preceding claim, wherein the venom was snake venom.

17. The tyrosine kinase inhibitor for use of claim 16, wherein the snake is of the Viperidae family.

18. The tyrosine kinase inhibitor for use of claim 16, wherein the snake is selected from the list consisting of: Bungarus caeruleus, Naja naja, Echis carinatus, Daboia russelii, Bitis arietans, Crotalus atrox, Bothrops atrox, Vipera berus, Micrurus obscurus, Oxyranus scutellatus, Dendroaspis polylepis, Acanthopis rugosus, Agkistrodon laticinctus, Agkistrodon contortrix, Agkistrodon bilineatus, Agkistrodon piscivorus, Agkistrodon taylori, Atractaspis fallax, Agkistrodon leucostoma, Bitis rhinoceros, Bitis nasicornis, Bothrops alternatus, Bothrops atrox from Suriname, Bothrops atrox from Columbia, Bothrops asper, Bothrops atrox from Guyana, Bungarus candidus, Bungarus fasciatus, Bothrops moojeni, Bothrops jararacussu, Calloselasma rhodostoma, Crotalus scutulatus scutulatus from Arizona, Craspedocephalus puniceus, Crotalus horridus, Crotalus scutulatus scutulatus from Texas, Crotalus viridis viridis, Deinagkistrodon acutus, Echis leucogaster, Echis pyramidum, Dendroaspis viridis, Echis ocellatus, Hypnale hypnale, Lachesis muta, Macrovipera lebetinus tauranica, Echis sochureki, Naja guineensis, Naja annulata, Montivipera xanthina, Metlapilcoatlus mexicanum, Naja nigricollis, Naja haje, Naja nana, Naja nivea, Naja savannula, Naja subfulva, Naja pallida, Ovophis okinavensis, Oxyuranus scutellatus scutellatus, Oxyuranus microlepidotus, Oxyuranus scutellatus canni, Protobothrops elegans, Trimeresurus insularis, Pseudechis colletti, Macrovipera mauritanica, Vipera ammodytes, Trimeresurus purpureomaculatus , Naja annulifera, and Naja mossambica.

19. The tyrosine kinase inhibitor for use of claim 18, wherein the snake is selected from the list consisting of: Bitis arietans, Vipera berus, Agkistrodon laticinctus, Agkistrodon bilineatus, Agkistrodon taylori, Agkistrodon leucostoma, Bitis nasicornis, Bitis arietans, Bothrops atrox from Columbia, Crotalus horridus, Lachesis muta, Oxyuranus scutellatus scutellatus, and Vipera ammodytes.

20. The tyrosine kinase inhibitor for use of any preceding claim, wherein the method further comprises administering an antivenom.

21. A kit comprising a tyrosine kinase inhibitor, and either or both of a PLA2 inhibitor and a matrix metalloprotease inhibitor.

22. A PLA2 inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprises administering a tyrosine kinase inhibitor, and optionally administering a matrix metalloprotease inhibitor.

23. A matrix metalloprotease inhibitor for use in a method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the method comprises administering a tyrosine kinase inhibitor, and optionally administering a PLA2 inhibitor.

24. A method of prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, the method comprising administering to the subject a tyrosine kinase inhibitor, wherein optionally the method further comprises administering to the subject a PLA2 inhibitor and / or administering to the subject a matrix metalloprotease inhibitor.

25. A PLA2 inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor, and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a matrix metalloprotease inhibitor.

26. A matrix metalloprotease inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a tyrosine kinase inhibitor, and optionally wherein the prevention, treatment, inhibition, delay and / or amelioration comprises the administration of a PLA2 inhibitor.

27. A tyrosine kinase inhibitor for use in the manufacture of a medicament for the prevention, treatment, inhibition, delay and / or amelioration of the effects of envenomation in a subject, wherein optionally the treatment further comprises the administration of a matrix metalloprotease inhibitor and / or the administration of a PLA2 inhibitor.

28. A pharmaceutical composition comprising a tyrosine kinase inhibitor and either or both of a PLA2 inhibitor and a matrix metalloprotease inhibitor.

29. The tyrosine kinase inhibitor for use of any one of claims 1 to 20, the PLA2 inhibitor for use of claim 22, the matrix metalloprotease inhibitor for use of claim 23, the method of claim 24, the PLA2 inhibitor for use in the manufacture of a medicament of claim 25, the matrix metalloprotease inhibitor for use in the manufacture of a medicament of claim 26, or the tyrosine kinase inhibitor for use in the manufacture of a medicament of claim 27, wherein the administration:a) improves survival rate after 48 hours compared to a control wherein no treatment is provided; and / orb) reduces haemorrhaging after 48 hours compared to a control wherein no treatment is provided.

30. The tyrosine kinase inhibitor for use of any one of claims 1 to 20 and 29, the PLA2 inhibitor for use of claim 22 or 29, the matrix metalloprotease inhibitor for use of claim 23 or 29, the method of claim 24 or 29, the PLA2 inhibitor for use in the manufacture of a medicament of claim 25 or 29, the matrix metalloprotease inhibitor for use in the manufacture of a medicament of claim 26 or 29, or the tyrosine kinase inhibitor for use in the manufacture of a medicament of claim 27 or 29, wherein the daily dosage of the tyrosine kinase inhibitor is from 150mg to 600mg.

31. The tyrosine kinase inhibitor for use of any one of claims 9 to 15 or any one of claims 16 to 20, 29 and 30 as dependent upon any one of claims 9 to 15, the PLA2 inhibitor for use of claim 22, 29 or 30 wherein the matrix metalloproteinase inhibitor is administered, the matrix metalloprotease inhibitor for use of claim 23, 29 or 30, the method of claim 34, 29 or 30 wherein the matrix metalloproteinase inhibitor is administered, the PLA2 inhibitor for use in the manufacture of a medicament of claim 25, 29 or 30 wherein the matrix metalloproteinase inhibitor is administered, the matrix metalloprotease inhibitor for use in the manufacture of a medicament of claim 26, 29 or 30, or the tyrosine kinase inhibitor for use in the manufacture of a medicament of claim 27, 29 or 30 wherein the matrix metalloproteinase inhibitor is administered, wherein the daily dosage of the matrix metalloprotease inhibitor is from 200mg to lOOOmg.

32. The tyrosine kinase inhibitor for use of any one of claims 5 to 8 and 14 to 15, or any one of claims 9 to 13 and 16 to 20, and 29 to 30 as dependent upon any one of claims 5 to 8 and 14 to 15, the PLA2 inhibitor for use of any one of claims 22 and 29 to 31, the matrix metalloprotease inhibitor for use of any one of claims 23 and 29 to 31 wherein the PLA2 inhibitor is administered, the method of any one of claims 24 and 29 to 31 wherein the PLA2 inhibitor is administered, the PLA2 inhibitor for use in the manufacture of a medicament of any one of claims 25 and 29 to 31, the matrix metalloprotease inhibitor for use in the manufacture of a medicament of any one of claims 26 and 29 to 31 wherein the PLA2 inhibitor is administered, or the tyrosine kinase inhibitor for use in the manufacture of a medicament of any one of claims 27 and 29 to 31 wherein the PLA2 inhibitor is administered, wherein the daily dosage of the PLA2 inhibitor is from 250mg to 1250g.